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1. Introduction
1.1 Adverse Drug Reactions (ADR)
Adverse drug reactions are a common clinical problem. It is estimated that ADRs
may occur in 16,88% of patients during hospitalization [89]. However, such estima-
tions need to be treated with caution due to the wide variation in methodologies
for ADR identification. Furthermore, these statistics do not include the number of
ADRs that occur in ambulatory settings. Among various target organs, skin is one
of the most frequent sites for ADRs [123]. ADRs can be classified either as type A
(dose-dependent) or as type B (idiosyncratic) [127]. Type A reactions are mostly
dose-dependent and predictable and are caused by overdosage, reduced elimination,
or drug-drug-interactions which result in an increased drug-plasma-concentration.
These kinds of reactions constitute 70-80% of ADRs [94]. Type B reactions are a
major cause of drug withdrawal both late in drug development and at the postmar-
keting stage [127]. They are considered to be unpredictable and are normally not
related to the pharmacologic activities of the drug [117]. They may comprise ap-
proximately 10-15% of all ADRs [94]. Idiosyncrasy, drug intolerance, pseudo-allergic
and allergic reactions of drugs are dedicated as type B reactions [127, 94].
1.1.1 Drug allergy
Drug allergy reactions, i. e. anaphylaxis, bronchospasm, dermatitis, fever, and hep-
atitis, are unpredictable idiosyncratic reactions that are difficult to prevent or manage
[94]. Such reactions are the result of a drug-mediated activation of the immune sys-
tem. In general, these reactions are not dose-dependent and can be triggered even
with relatively small active substance amounts. They represent a major problem
in both clinical treatment and drug development [145]. Allergic drug reactions ac-
count for approximately 5-10% of all ADRs [119]. Allergy to beta-lactams continues
to be the most frequent cause of drug reactions [17, 77]. Of all patients treated
with penicillins, 0,7 to 10% develop an allergic reaction [55]. Sulphonamides also
induce allergic reactions, however, in opposite to β-lactam antibiotics they need to
be transformed by xenobiotica metabolizing enzymes to result in the formation of
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the nominative antigen [29, 128].
The skin represents the most frequent site for drug-induced allergic reactions. An-
tibiotics provoke diseases like maculopapular, pustular, or bullous exanthemas, the
Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), which can
also be life-threatening [122]. Sulfonamide antibiotics are often associated with de-
layed cutaneous maculopapular eruptions, SJS and TEN [157]. Therefore, it is es-
sential to recognize these reactions, and the European Network for Drug Allergy
(ENDA)/European Academy of Allergy and Clinical Immunology (EAACI) has stan-
dardized the guidelines for the diagnosis of allergic reactions to drugs [27]. Besides
a comprehensive medical history and physical examination of the patient [94], skin
tests [21] and drug provocation tests [3] are carried out to confirm the diagnosis.
In vitro tests like the Lymphocyte Transformation Test (LTT) are of great interest
due to a reduction of drug provocation challenges and consecutive severe reactions
[103, 114].
Drug allergy reactions are generally classified according to Coombs and Gell [35].
Type I reactions, or so-called immediate-Th2-type reactions, are mediated by drug-
specific IgE antibodies and cause reactions such as urticaria, anaphylaxis, and asthma
[5]. Immediate reactions occur within one hour after the drug intake. Type II com-
prises IgM and IgG-cytotoxic mechanisms (e. g. blood cell dyscrasias). Type III
are related to soluble IgG and IgM immune complexes (e. g. vasculitis, nephritis).
Type IV reactions are T-cell-mediated reactions that include distinct manifestations
according to the kind of cytokines secreted by T cells [94]. β-lactams provide the
best model to analyze immediate-type or delayed-type immune-mediated reactions
[121].
Drug allergy reactions can often be observed as a combination of reaction types that
do not allow the strict classification in reaction types I-IV. Immunological hypersen-
sitivity reactions can mainly be divided into antibody- and cell-mediated reactions
with further subclassifications (fig. 1.1) [145].
1.2 Delayed-type hypersensitivity (DTH) reactions
Delayed type hypersensitivity (DTH) reactions are T-cell-mediated type IV allergic
reactions. They generally occur after 24 to 72 hours of the drug intake [30]. Organs
involved in DTH reactions are the skin, the liver, the kidney, and the hemolytic
system. As observed with all allergic reactions, a distinction is made between the
sensitization phase and the elicitation phase characterized by the drug-induced acti-
vation of T-cells. T-cells infiltrate the tissue and cause organ damage and produce
cytokines that mediate antibody class switching [5]. Because of the complexity of
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Figure 1.1: Classification of hypersensitivity reactions
DTH reactions, T-cell-mediated type IV reactions were subclassified in IVa-IVd reac-
tions. Type IVa reactions correspond to Th1 immune reactions. Type IVb reactions
correspond to the Th2 type immune response [5]. Type IVc reactions describe re-
actions where T-cells act as effector cells. They emigrate into the tissue and kill
cells in a perforin/granzymeB and/or FasL-dependent manner [97, 163]. Type IVd
reactions take into account that T-cells driven by an antigen can coordinate (sterile)
neutrophilic inflammation [5]. It is assumed that the development of T-lymphocyte
subpopulations may also be driven by dendritic cells (DC) of different phenotypes
[34, 142].
Allergic contact dermatitis (ACD) is one of the most studied forms of xenobiotic-
induced DTH, in which topical application and elicitation of sensitization to xenobi-
otics is confirmed to the skin [123]. Lessons on the pathophysiology of drug-induced
DTH reactions can be learnt from studies with contact sensitizers [85].
1.2.1 Haptens
DTH reactions are mainly caused by haptens. A drug has to provide immunogenic
properties to act like an antigen and to be able to initiate an immune reaction.
The immunogenicity is dependent on the molecular size of a drug. The smallest
immunogenic peptides consist of approximately seven amino acids. A weak immuno-
gen has a molecular mass of 700-800Da. Most drugs do not reach the size that
would be necessary for the induction of an immune response. Drugs bind to carrier
molecules to become the nominative antigen. Carriers can be any kind of autolo-
gous protein, like soluble extracellular proteins (e. g. albumin), membrane proteins
(e. g. an integrin) and intracellular proteins (e. g. enzymes) or possibly directly the
peptide embedded in the major histocompatibility complex (MHC) molecule itself
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[5]. Low-molecular-weight drugs covalently bind to proteins, but they rarely bind to
heavy metals via chelate complex formation [55]. Low-molecular-weight drugs and
low-molecular-weight contact allergens can form haptens.
The penicilloyl-groups of β-lactam antibiotics form hapten-carrier conjugates with
proteins that can be processed and presented by antigen-presenting cells (APCs) to
naive T-lymphocytes [77]. It has been shown that penicillin derivatives were prone
to binding covalently to lysine residues of serum albumin [135].
1.2.2 Prohaptens
Few drugs possess reactive functional groups for covalently binding to other pro-
teins. Reactive functional groups seldom arise spontaneously in the plasma, like
the β-lactam ring of penicillins. Most drugs gain reactive groups (acid anhydrides,
acid chlorides, reactive aromatic halides, isocyanates, thiols, quinones) after metab-
olization. The liver represents the primary site of bioactivation for most drugs, but
metabolism may also occur in organs such as the skin, the kidney, and the gut. APCs
also represent metabolizing cells [127]. Albumin is a protein acceptor naturally pro-
duced in the body [55].
Sulfamethoxazole (SMX) is a prototype of such a pro-hapten. It is itself not chemi-
cally reactive but gains reactivity, thus, antigenicity by intracellular metabolism. A
cytochrome P450-dependent metabolism (CYP2C9) in the liver leads to sulfamethoxa-
zole-hydroxylamine (SMX-NHOH) which can be found in the urine, and which is
easily converted to sulfamethoxazole-nitroso by oxidation [5]. SMX was found to
be converted to its Hydroxylamine-, Nitroso-, or N-chloro-metabolite by CYP2C9,
CYP2E1, CYP3A4, and myeloperoxidase [25, 26, 152].
1.2.3 Dendritic cells
Dendritic cells are APCs essential for initiating T-cell responses, which are widely
distributed throughout the body. Their abilities are regulated in a process known
as maturation where they modulate the tolerant or the effector immune responses
mediated by different subtypes of T lymphocytes [121] by expressing a unique set of
costimulatory molecules (HLA-DR, CD86, CD80). DCs can secrete a diverse panel
of chemokines that attract different cell types at different times of the immune re-
sponse [77].
Many studies have supported the role of DCs in the response to haptens. For a large
number of molecules it was shown that haptenization by itself leads to the production
of a maturative state in the DCs that induces a specific T-cell response [121, 7, 82].
For this reason, haptenization itself is thought to be pro-inflammatory [5].
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In lymphnodes, DCs present their peptide fragments over MHC I or MHC II re-
ceptors to T-helper cells (CD4+) or cytotoxic T-cells (CD8+). Haptenized proteins
need to be processed by APCs to produce haptenized peptides presented on MHC
molecules [5]. Additionally, T-cells can be stimulated by processed peptides derived
from conjugated protein [95].
Hapten/prohapten concept The hapten/prohapten concept posits that low-molecular
weight drugs or reactive drug metabolites following haptenation to self-proteins and
formation of neoantigens are recognized by T-cells to override self-tolerance and in-
duce a potentially pathogenic immune response [127]. For instance, this mechanism
has been well documented for the contact sensitizer trinitrobenzene sulfonic acid
(TNBS) [109, 115].
p-i-concept Recently, an alternative hypothesis to the hapten- and prohapten con-
cept known as the p-i-concept (pharmacological interactions of drugs with immune
receptors) has been proposed [112]. It is assumed that chemically inert drugs can
reversibly interact with the T-cell receptor directly in the absence of metabolism,
covalent binding, and processing. The T-cell receptor with the bound drug interacts
with the MHC-molecules on dendritic cells which leads to the activation of T-helper-
and cytotoxic T-cells. Carbamazepin has been discussed to act according to the
p-i-concept [96].
‘Danger signal’ In addition to ‘signal 1’, which is the T-cell-receptor-mediated
recognition of an MHC-restricted antigen, a second ‘signal’ is necessary for the
effective activation of the adaptive immune system. ‘Signal 2’ represents the in-
teractions between various costimulatory ligands and receptors between the T-cell
and the APC [127]. The ‘danger hypothesis’, postulated by Polly Matzinger [79],
implies that ‘danger signals’, such as cell damage or infection, activate the immune
system via the ‘signal 2’ pathway by upregulating costimulatory markers on APCs.
Because of their intrinsic protein reactivity, contact sensitizers are often toxic to DCs
at relatively low concentrations [127]. They have been found to provoke ‘signal 2’ by
either upregulation of cell surface markers, such as CD80, CD86, CD40, and HLA-
DR [144, 151], or chemokine receptors [53], or by activation of signal transduction
pathways [8, 109, 115].
Xenobiotic metabolism As mentioned before, prohaptens need prior activation to
become sensitizing. This activation process can occur by the xenobiotic-metabolizing
CYP450 enzymes. Intriguingly, Saeki et al. [125] showed that some cytochrome P450
(CYP450) isoenzymes are expressed in Langerhans cells of the skin, and Sieben et al.
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[139] showed that multiple CYP450 isoenzymes are expressed in monocyte-derived
dendritic cells (moDCs). The prohapten carvoxime was found to act as an inducer
of P450 1B1 in human moDCs and was found to mediate a transcriptional gene ex-
pression change of IL-8 [108].
Efflux transporter proteins like the multidrug resistance-associated proteins (MRPs)
and influx transporter proteins like the organic anion transporting polypeptides
(OATPs) might also be involved in the xenobiotic metabolism of dendritic cells.
The differential mRNA expression of these transporters could be shown in human
primary APCs [140]. Furthermore, Skazik et al. [141] found that the transport of the
contact allergen eugenol in moDCs is mediated by MRP1. Incubation of moDCs with
isoeugenol after pre-treatment with the MRP1-inhibitor indomethacin increased the
gene expression of sensitizing markers (IL-8 and TRIM16) [141].
A better understanding of DC involvement in responses to haptenic drugs is needed,
because it represents a possible approach to the development of an in vitro test,
which could identify patients prone to drug allergies [77].
1.2.4 Dendritic cells in the development of cell-based assays for assessing the
skin-sensitization potential of chemicals in vitro
A complete ban on animal testing for cosmetic ingredients will be put into place
by the 7th Amendment to the cosmetics directive (Directive 76/768/EEC) in 2013.
This announcement led to the development of novel cell based in vitro assays for
the detection of a sensitizing potential of cosmetic ingredients such as fragrances.
Therefore, alternative cell-based in vitro test systems for their potential to detect the
sensitizing potential of fragrances were evaluated [109, 115, 108, 110]. These in vitro
test systems focus on the chemical-induced stimulation of moDCs or myeloid-/DC-
like cell lines e. g. THP-1, U937, KG-1 and MUTZ-3 and the following measurement
of phenotypic alterations, cytokine secretion and differential gene regulation [14, 109,
115, 141]. Ott et al. [109] showed that genes involved in oxidative and metabolic stress
responses (CES1, NQO1, GCLM), in immunological reactions (IL-8, IL-1β), or in
transcriptional regulation processes (PIR, TRIM16) are up-regulated after treatment
of moDCs with the contact sensitizers TNBS or cinnamic aldehyde by exon array
analysis. A comparative DNA microarray analysis of moDCs and MUTZ-3 cells
exposed to cinnamic aldehyde revealed similar results [115].
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1.3 Drug transporter
Adverse drug reactions initiated by drug interactions can occur in the liver, GI tract,
and skin due to changes in the rates of drug metabolism. Drug interactions can
also occur through competition at drug transporters. Genetic polymorphisms can be
a possible factor for drug allergies. Clinical pharmacokinetic drug-drug interaction
studies have suggested that transporters like the MRPs and the OATPs often work
together with drug-metabolizing enzymes like the CYP450-dependent enzymes [147].
The skin represents a major target organ for xenobiotic metabolism. The metabolism
process can be divided into at least three phases: ‘phase I’ involving the activation of
the xenobiotics by oxidation through cytochrome P450 (CYP) enzymes; ‘phase 2’ in
which the highly reactive metabolite is further metabolized by other enzymes, such as
transferases, to more water-soluble metabolites that can leave the cells; and ‘phase 3’
that is mediated by influx and efflux transporter proteins (fig. 1.2). Members of this
transporter proteins could be shown to be expressed in keratinocytes and dendritic
cells [84, 141].
Figure 1.2: Xenobiotica metabolism in the skin. The skin possesses an armentarium of
enzyme-mediated xenobiotica metabolism, including cytochrome P450 isoenzymes, en-
zymes of the phase II reaction such as epoxide hydrases, reduced nicotinamide adenine
dinucleotide phosphate quinine reductases, transferases as well as influx and efflux trans-
porter molecules.
‘Phase I’, CYP; ‘phase II’, epoxide hydrases/transferases; ‘phase III’, transporter proteins.
In addition, it was found that small molecular weight compounds are transported into
and out of a cell by specific transporter molecules. Their expression is closely linked to
the expression of CYP enzymes. ABCC, ATP-binding cassette C transporters; CYP, cy-
tochrome P450; MDR, multidrug resistance; MRP, multidrug resistance protein; NQR,
nicotinamide adenine dinucleotide phosphate quinine reductases; OATP, organic anion
transporting polypeptides; SLCO, solute carrier organic anion transporter [84].
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1.3.1 Organic anion transporting polypeptides (OATPs)
The OATP family
The organic anion transporting polypeptide (OATP) family belongs to the gene
superfamily of solute carriers (SLC) and is classified within as gene family SLC21A.
Eleven members of the OATP family have been identified in human tissues encoded
by genes named SLCO (solute carrier organic anion transporter) [40]. Multiple
OATPs/Oatps from different species including human, rat and mouse have been
cloned [40, 90]. The first Oatp family member identified in 1994 by expression
cloning was rat Oatp1a1 [50].
Mammalian OATPs/Oatps are classified based on amino acid sequence homology into
families and subfamilies. OATPs/Oatps within the same family share more than 40%
amino acid sequence identity and are designated by arabic numbering (1-6), while
proteins with identities of more than 60% are classified within the same subfamily,
designated by letters (A-D). Individual gene products within the same subfamily
are designated by additional arabic numbering (1-6). Based on this classification
system, the eleven human OATPs are grouped in six families (fig. 1.3) [38]. The
first discovered human member was OATP1A2, which shares 67% sequence identity
to rat Oatp1a2 [63]. Interestingly, OATP family members are poorly conserved
evolutionarily, and orthologues for human OATPs may not exist in rodents [147].
Figure 1.3: Phylogenetic tree of the OATP-gene superfamily. OATPs/Oatps with more
than 40 % amino acid sequence identity are classified in the same family (OATP1, OATP2,
OATP3, OATP4, OATP5, and OATP6). Members with more than 60 % are classified in
the same sub-family (e. g. OATP1A, OATP1B, and OATP1C). Human OATPs are given in
all capitals, all other species are indicated with a small letter preceding the protein symbol
Oatp. b, bovine; c, chicken; m, mouse; r, rat; s, skate [38].
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Structure of OATPs
The general predicted OATP structure consists of proteins with twelve transmem-
brane domains yielding six extracellular and five intracellular loops with both N-and
C-termini facing the cytosol [38]. Fig. 1.4 shows a cartoon representation of the
structural model of OATP1B3 [83]. According to the structure of MFS (Major Facil-
itator Superfamily) proteins, OATP1B3 consists of six N-terminal and six C-terminal
helices which are located around the central pore. A positive electrostatic potential
exposed to an aqueous face should facilitate binding and transport of negatively
charged compounds [83, 146].
Several conserved structural domains have been identified in OATPs. The OATP
superfamily signature, thirteen amino acids in length, contains three conserved tryp-
tophan residues and is described by the motif [D-X-RW-(I,V)-GAWW-X-G-(F,L)-L].
The signature is located at the border of the extracellular domain three and the
transmembrane domain six [146, 40, 39]. A Kazal-1/2-type serine protease inhibitor
domain was found to be located in the extracellular loop region five between helix
nine and helix ten [83]. A typical Kazal domain contains six cysteine residues lead-
ing to three disulfide bonds with a 1-5/2-4/3-6 pattern [68]. OATPs are the only
example of this structure found as a domain in an integral membrane protein, but
the precise function of this hydrophilic domain is still unknown [83]. It may regulate
the presentation of the substrate to the transporter or the interaction with other pro-
teins [146]. Furthermore, some OATPs share a PDZ domain (post-synaptic density
protein (PSD95), Drosophila disc large tumor suppressor (Dlg1), zonula occludens-1
protein (ZO-1)). PDZ domains help anchor transmembrane proteins to the cytoskele-
ton and hold together signaling complexes [116]. Plasma membrane localization of
OATP1A2, OATP3A1, and OATP1C1 seems to be dependent on interactions with
PDZ proteins [57]. Other OATPs like OATP2A1 and OATP5A1 lack a PDZ motif
[146].
Transport function of OATPs
OATPs form a family of influx transmembrane transporters expressed in various
tissues, including liver, kidney and brain (table 1.1). They mediate the sodium-
independent transport of a diverse range of mainly amphiphatic organic compounds
with molecular weights of more than 300 kDa, including bile acids (e. g. Taurocholate,
Glycocholate), steroid conjugates (e. g. Dehydroepiandrosterone-3-sulfate (DHEAS),
Estradiol-17β-glucoronide), thyroid hormones (e. g. Thyroxine (T4), Triiodthyronine
(T3)), anionic peptides (e. g. Microcystin), numerous clinically important drugs (e. g.
Digoxin, Methotrexate) [101], and other xenobiotic substances [149]. Interestingly, a
number of OATPs share substrate specificity with some cellular efflux pumps, such as
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Figure 1.4: Cartoon representation of the structural model of OATP1B3, viewed from
(a) the intracellular side, (b) the extracellular side and (c) the lateral side. Helices are
shown as cylinders and rainbow-coloured. The zooming is identical for (a-c). The approx-
imate positions of the membrane bilayer and of the N and C termini are indicated in (c).
(d) OATP1B3 substrate digoxin (shown in cyan as stick model) fitted into the pore of the
OATP1B3 structural model, viewed from the intracellular side (in approximately the same
orientation as (a) but zoomed in). The docking was performed by GOLD [154]. The figure
was generated with PyMOL (www.pymol.org) [83].
multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein
2 (MRP2) [39].
The skin, known for its metabolizing abilities [13, 28, 140, 141], represents also a
tissue for OATP transport. Schiffer et al. [132] have shown that OATP2B1 (OATP-
B), OATP3A1 (OATP-D) and OATP4A1 (OATP-E) are constitutively expressed
in normal human epidermal keratinoytes (NHEKs). The uptake of estradiol-17β-D-
glucoronide and estrone-3-sulfate was inhibited by taurocholate in NHEKs [132]. The
differential expression of SLCO transporters in human primary antigen presenting
cells might regulate the influx of exogenous molecules like allergens or drugs but also
of endogenous substances like inflammatory lipid mediators [140].
A common transport mechanism has been proposed for all OATPs/Oatps, in which
substrates are translocated through a central, positively charged pore in a rocker-
switch-type mechanism [83]. However, it is unclear whether this transport mode
involves the coupled movement of another solute across the membrane or if it occurs
by facilitated diffusion through the putative central pore [146].
Regulation of OATP Expression
It is assumed that OATPs can indirectly regulate their transporter expression by in-
fluencing the intracellular concentration of nuclear receptor ligands such as the preg-
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Table 1.1: Characteristics of human OATP family members [61, 146, 104]
Gene symbol Protein name Chromosomal Amino Acids Tissue
localization distribution
SLCO1A2 OATP1A2 12p12 670 Blood-brain barrier, Kidney,
Cholangiocytes, Enterocytes
SLCO1B1 OATP1B1 12p12 691 Liver
SLCO1B3 OATP1B3 12p12 702 Liver
SLCO1C1 OATP1C1 12p12 712 Brain, Testis, Ciliary body
SLCO2A1 OATP2A1 3q21 643 Ubiquitous
SLCO2B1 OATP2B1 11q13 709 Liver, Placenta, Intestine,
Blood-brain barrier, Heart,
Enterocytes
SLCO3A1 OATP3A1 15q26 710 Ubiquitous
SLCO4A1 OATP4A1 20q13.1 722 Ubiquitous
SLCO4C1 OATP4C1 5q21 724 Kidney, Lung, Skin
SLCO5A1 OATP5A1 8q13.1 848 Heart, Brain, Skeletal Muscle,
Lactiferous ducts in breast
SLCO6A1 OATP6A1 5q21 719 Testis
nane X receptor (PXR), the constitutive androstan receptor (CAR), the farnesoid
receptor (FXR), the liver X receptor (LXR), the peroxisome proliferator-activated
receptor alpha (PPARα), or the hepatocyte nuclear factor 4 (HNF4) resulting in
changed drug transport [87, 86, 88]. For example, the PXR agonist rifampicin lead
to a down-regulation of OATP1B3 while phenobarbital increased the expression of
OATP1B3 [146, 106].
Cytokines may also affect OATP transporter expression. In human hepatocytes it
was shown that TNFα and IL-6 concomitantly reduced OATP1B1 protein expression
and OATP1B1-mediated transport [146, 72].
Furthermore, promoter regions of organ-specific OATPs may be regulated by DNA
methylation. A recent study in colon cancer cell lines revealed a different methyla-
tion pattern around the transcriptional start site of OATP1B3, which may explain
the distinct expression pattern observed in this cell lines [146, 47].
Posttranslational modifications such as glycosylation are assumed to be important
for membrane localization and transport function [146, 73].
The protein kinase C (PKC) pathway may also be involved in OATP regulation.
Increased phosphorylation mediated by PKC led to a rapid clathrin-dependent in-
ternalization of OATP2B1 and lysosomal degradation [146, 59].
Role of OATP transporters in adverse drug reactions
Numerous sequence variations, such as single nucleotide polymorphisms (SNPs), have
been identified in SLCO genes [150, 102, 101, 24]. Several of these SNPs as well as in-
teractions of drugs with co-administered drugs have been linked to altered disposition
of chemotherapeutic drugs and consequently increased adverse effects, confirming the
importance of OATPs in the disposition of drugs [104].
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Drug-drug interactions The inhibition of uptake transport proteins can be respon-
sible for alterations in the plasma concentration of concomitantly administered drugs
[61]. Studies in stably transfected HEK cells expressing OATP1B1 and OATP1B3
showed that the macrolides clarithromycin, erythromycin, and roxithromycin inhib-
ited pravastatin uptake [137].
The stimulation of uptake rates should also be taken into account as possible fac-
tor for altering drug plasma concentrations. The inhibition of OATP1B1- and
OATP1B3-mediated uptake of pravastatin by the oral antidiabetic drug repaglin-
ide occured at a low concentration of 10 µM as demonstrated in HEK293 cells. In
contrast, the oral antidiabetic drug rosiglitazone stimulated the uptake of pravas-
tatin at the same low concentration and inhibited pravastatin uptake only at a high
concentration of 100 µM [12].
Genetic variations SNPs and different haplotypes of allelic variants may have con-
sequences on protein localization and transport function [62]. Most of the variations
identified in OATPs are located within transmembrane-spanning regions or in the
second or fifth extracellular loop, suggesting that these protein regions are important
for substrate recognition and/or transport [61, 150]. The first detailed in vitro anal-
ysis of 14 nonsynonymous polymorphisms in OATP1B1 were investigated by Tirona
et al. [150]. SNPs resulted in altered transport kinetics. For example, the haplotype
OATP1B1*13 (SLCO1B1c.245T>C/c.467A>G/c.2000A>G) significantly increased
the Km value for estrone-3-sulfate from 0,54 to 2,2 µM.
1.3.2 Organic anion transporting polypeptide 5A1 (OATP5A1)
Human OATP5A1 (fig. 1.5) is the only member in the OATP5 family and also the
only member in the OATP5A sub-family that contains single members of rat and
mouse [40]. The putative protein contains 848 amino acids with a calculated molecu-
lar mass of 92 kDa. According to the NCBI-Gene website, alternative splicing results
in transcript variants (793 aa/86 kDa, 687 aa/75 kDa). Among the other SLCO fam-
ily members, SLCO5A1 is the only gene which is located on chromosome 8 (8q13.3).
High mRNA levels were detected in the brain, heart, skeletal muscle, and ovary
[105]. Transcriptional expression of SLCO5A1 was observed in human bone tumors,
in prostate cancer [76] and in normal and cancerous breast tissue [160]. A recent
publication determined SLCO5A1 mRNA expression in primary liver cancer and
liver metastases from colon tumors [161]. Expression of SLCO5A1 was also found
in drug-resistant small cell lung cancer (SCLC) cells [107]. SLCO5A1 expression
studies in human primary APCs showed that the solute carrier is highly expressed
in dendritic cells (own unpublished data).
OATP5A1 protein was only described by two publications, which analyzed OATP5A1
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expression by immunohistochemistry and immunofluorescence of paraffin-embedded
tissue samples. OATP5A1 was found at the plasma membrane of epithelial cells of
the lactiferous ducts in normal breast tissue and at the plasma membrane and in the
cytoplasm of malignant breast tumor specimens [60]. OATP5A1 protein was also
observed in plasma membranes and cytosol of hepatic tumor cells, and additionally,
in various cytokeratin 19 positive bile ducts [161]. An expression profile of OATP5A1
protein can be viewed at www.proteinatlas.org [1] with the strongest expression in
cortical cells of the adrenal gland and follicle cells of the ovary, though the specificity
of the used antibody needs to be determined (polyclonal rabbit anti-SLCO5A1 only
tested for immunohistochemistry of paraffin-embedded tissue samples).
Figure 1.5: Topological model of hOATP5A1, as drawn with TeXtopo [15]. The indi-
cated location of the transmembrane segments (TMI-TMXII) (yellow) was calculated with
the topology prediction program MEMSAT3.0 [51]. The C-terminal His tag (green) and
the positions of the six luminally located N-glycosylation sites (blue) are indicated. The
Kazal-like domain is located in the extracellular loop region five and ranges from amino
acid 548 to amino acid 603. Human OATP5A1 lacks the PDZ domain found in other
OATP family members.
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1.4 Aims of this thesis
The current in vitro methods to confirm diagnosis of drug-induced hypersensitiv-
ity reactions and to identify the culprit drug are still unreliable and have not been
standardized [77]. Few studies, e. g. Rodriguez-Pena et al. [121], Lima et al. [77],
are dealing with the involvement of DCs in DTH to drugs. Currently, most in vivo
tests like animal based experiments and, in a later phase, clinical studies are used
to evaluate the putative sensitizing potential of novel drugs. To find out whether
in vitro assays developed to predict the sensitizing potential of cosmetic compounds
might also be used for the pre-screening of drugs, well-studied model compounds
such as beta-lactams and sulphonamides were co-incubated with human APCs, and
differential regulation of potential marker genes (IL-8, IL-1β, PIR, TRIM16, CES1,
NQO1, GCLM) was measured by qRT-PCR. It was the aim of the first part of this
thesis to analyze whether the different APC cell systems identify the most promis-
ing cell type and marker genes for the measurement of the sensitization potential
of antibiotics. The study should also clarify whether these systems are capable of
detecting antibiotics acting as prohaptens.
The human member of the organic anion transporting polypeptide family OATP5A1
was found to be expressed in the epithelium of many cancerous and non-cancerous
tissues throughout the body. Interestingly, a high SLCO5A1 expression could be
detected in primary dendritic cells but not in macrophages. Although there are indi-
cations about OATP5A1 protein expression, so far, OATP5A1 cell localization and
function has not been further characterized and substrates have not yet been deter-
mined. It was the aim of the second part of this thesis to molecularly characterize
human OATP5A1 expressed in oocytes of the south-african clawed frog Xenopus lae-
vis and genetically modified Hela cells (‘FlpIn T-Rex-Hela’). Furthermore, evidence
regarding a possible OATP5A1 function should be provided.
2. Results
The chapter ‘Results’ is divided into two parts. In the first part, the sensibilization
of antigen-presenting cells (APCs) by low molecular weight drugs was measured. In
the second part, the molecular characterization of the organic anion transporting
polypeptide OATP5A1 was described in genetically modified Hela cells (‘FlpIn T-
Rex Hela’) and oocytes of the clawed frog Xenopus laevis. Functional assays should
reveal the importance of OATP5A1.
2.1 Sensibilization of APCs by low-molecular weight drugs
To determine whether in vitro assays developed to predict the sensitizing potential
of cosmetic compounds might also be used for the pre-screening of drugs, model
compounds such as betalactams and sulphonamides were studied.
To evaluate the suitability of the in vitro test system, three human cell types were
used: the human monocytic-like cell line THP-1, the CD34+ acute myeloid leukemia
cell line MUTZ-3, differentiated towards langerhans-like cells (MUTZ-LCs), and pri-
mary monocyte-derived dendritic cells (moDCs). To detect the sensitization po-
tential, the differential expression of selected marker genes for enzymes involved in
xenobiotic metabolism, e. g. CES1, NQO1 and GCLM, for inflammatory cytokines,
e. g. IL-8 and IL-1β, and for transcription factors involved in cell differentiation, e. g.
PIR and TRIM16, were measured using quantitative real-time PCR (qRT-PCR) (ta-
ble 2.1).
In preliminary experiments, optimal concentrations for the used substances (cell vi-
ability higher than 75%, as assessed by PI/annexinV staining and flow cytometry
analysis) were determined. Stimulation of marker genes was measured for 24h, 30h,
48h and 72h with benzylpenicillin. The highest induction of the majority of marker
genes could be observed after 48h (data not shown). The strong contact allergen
trinitrobenzene sulfonic acid (TNBS) and the irritant sodium dodecyl sulfate (SDS)
were used as positive and negative controls, respectively.
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Table 2.1: Marker genes involved in the DTH reaction to β-lactam antibiotics
EntrezGene ID Gene symbol Full name Characteristics and Process
(Gene Ontology)
Immunological
Reactions
3576 IL-8 Interleukin 8 Inflammatory response,
neutrophil chemotaxis,
regulation of cell adhesion
3553 IL-1beta Interleukin 1 beta Inflammatory response, cell
proliferation, differentiation,
and apoptosis
Oxidative/Metabolic
stress response
1066 CES1 Carboxylesterase 1 Hydrolysis or
transesterification of various
xenobiotics with ester,
thioester, or amide bonds
1728 NQO1 NAD(P)H Reduction of quinones to
dehydrogenase, hydroquinones, prevents the
quinone 1 production of radical species
2730 GCLM Glutamate-cysteine Cysteine/glutamate metabolic
ligase, modifier process (first rate limiting
subunit enzyme of glutathione
synthesis)
Transcriptional
regulation
8544 PIR Pririn (iron-binding Transcriptional cofactor,
(TRIM20) nuclear protein) regulation of DNA
(Tripartite-motif transcription and replication
containing protein 20)
10626 TRIM16 Tripartite-motif Cell growth, differentiation and
containing protein 16 pathogenesis (function has
not yet been determined)
2.1.1 THP-1 cells
Using THP-1 cells, benzylpenicillin (PenG) and phenoxymethylpenicillin (PenV) en-
hanced the expression of the genes CES1, NQO1, GCLM, PIR, TRIM16 and IL-1β,
whereas ampicillin induced only CES1 and NQO1 (fig. 2.1 and fig. 2.2). In contrast,
sulfamethoxazole (SMX) did not induce the expression of the analyzed marker genes
except for PIR. The strongest expression could be detected for NQO1 after incu-
bation of THP-1 cells with 2,5mg/ml PenV (17-fold increase of expression). Most
interestingly, the gene for the inflammatory chemokine IL-8 was neither stimulated
by the contact allergen TNBS nor by the penicillins nor sulphonamide. It is note-
worthy that IL-1β upregulation was induced by the penicillins PenG and PenV but
not by TNBS.
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Figure 2.1: TaqMan real-time PCR analysis of mRNA expression in THP-1 cells after
treatment with TNBS, SDS, benzylpenicillin (PenG), phenoxymethylpenicillin (PenV),
ampicillin (Amp), sulfamethoxazole (SMX) and DMSO (control) for 48h, normalized
against GAPDH. The data shown are mean values ± standard deviation of 3 experiments.
The relative RNA levels of each candidate gene are presented as x-fold regulation com-
pared to mRNA expression of the analyzed gene regulation in untreated cells (medium)
except for SMX, where regulation is compared to the gene regulation of DMSO-stimulated
cells. *p<0,05; **p<0,005.
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Figure 2.2: TaqMan real-time PCR analysis of mRNA expression in THP-1 cells after
treatment with TNBS, SDS, benzylpenicillin (PenG), phenoxymethylpenicillin (PenV),
ampicillin (Amp), sulfamethoxazole (SMX) and DMSO (control) for 48h, normalized
against GAPDH. The data shown are mean values ± standard deviation of 3 experiments.
The relative RNA levels of each candidate gene are presented as x-fold regulation com-
pared to mRNA expression of the analyzed gene regulation in untreated cells (medium)
except for SMX, where regulation is compared to the gene regulation of DMSO-stimulated
cells. *p<0,05; **p<0,005.
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2.1.2 moDCs
Primary moDCs displayed a phenotype characteristic for immature dendritic cells
(DCs), i. e., CD1ahigh, CD80intermediate, CD86intermediate, CD83negative, CD14negative,
CD40intermediate (fig. 2.3).
Figure 2.3: Flow cytometric analysis of CD-antigens characteristic for immature DCs.
red: isotype control, grey: immature DCs.
When treated with both PenG and PenV as well as with TNBS, all of the marker
genes studied were stimulated (fig. 2.4 and fig. 2.5). Expression of the inflammatory
chemokine IL-8 could also be observed on protein level (fig. 2.6). The highest induc-
tion of marker gene expression could be detected with PenG and PenV, particularly
for the genes CES1 and IL-8. PenG showed a 29-fold upregulation for CES1 and a
34-fold upregulation for IL-8. PenV stimulated CES expression 11-fold and IL-8 ex-
pression 24-fold. Ampicillin and SMX differed from the penicillins PenG and PenV.
Ampicillin did affect the gene expression of the marker genes NQO1, GCLM, PIR
and TRIM16, whereas SMX did not induce the expression of the marker genes ex-
cept for PIR, similar to the observation in THP-1 cells. Interestingly, IL-8 cytokine
release could also be detected with SMX. In addition, it was found that GCLC, the
catalytic subunit of the glutamate-cysteine ligase (GCL), and the IL1 type 1 receptor
for IL-1β, are not induced by PenG (data not shown).
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The THP-1 cell line compared to moDCs reacted similarly with respect to marker
genes for xenobiotic metabolism and differentiation, even though the degree of gene
induction appeared to be cell-specific.
Figure 2.4: TaqMan real-time PCR analysis of mRNA expression in moDCs after treat-
ment with TNBS, SDS, benzylpenicillin (PenG), phenoxymethylpenicillin (PenV), ampi-
cillin (Amp), sulfamethoxazole (SMX) and DMSO (control) for 48h, normalized against
GAPDH. Data of 6 experiments are displayed as vertical box plot diagrams (Cleveland
method). The median is shown as well as the 25th and 75th percentiles. The graph whisker
caps are representing the 10th and 90th percentiles of data. The relative RNA levels of each
candidate gene are displayed on a log scale and presented as x-fold regulation compared
to the gene regulation in untreated cells (medium) except for SMX, where regulation is
compared to the gene regulation of DMSO-stimulated cells. *p<0,05; **p<0,005.
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Figure 2.5: TaqMan real-time PCR analysis of mRNA expression in moDCs after treat-
ment with TNBS, SDS, benzylpenicillin (PenG), phenoxymethylpenicillin (PenV), ampi-
cillin (Amp), sulfamethoxazole (SMX) and DMSO (control) for 48h, normalized against
GAPDH. Data of 6 experiments are displayed as vertical box plot diagrams (Cleveland
method). The median is shown as well as the 25th and 75th percentiles. The graph whisker
caps are representing the 10th and 90th percentiles of data. The relative RNA levels of each
candidate gene are displayed on a log scale and presented as x-fold regulation compared
to the gene regulation in untreated cells (medium) except for SMX, where regulation is
compared to the gene regulation of DMSO-stimulated cells. *p<0,05; **p<0,005.
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Figure 2.6: moDCs were stimulated with control substances (SDS, TNBS, DMSO) and
antibiotics for 48h. Supernatants were collected and IL-8 protein was measured by IL-8
immunoassay. Data of 6 experiments are displayed as vertical box plot diagrams (Cleve-
land method). The median is shown as well as the 25th and 75th percentiles. The graph
whisker caps are representing the 10th and 90th percentiles of data. *p<0,05.
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2.1.3 MUTZ-LCs
The effect of antibiotics in an additional cell line, which is supposed to resemble the
skin-typic langerhans dendritic cells (MUTZ-LCs), was also studied, but inconsistent
results were obtained (fig. 2.7 and fig. 2.8). The MUTZ-LCs showed a high variance
in three independent experiments as evidenced by the finding that a particular gene
was regulated in one experiment but not in the other two or vice versa. The positive
control substance TNBS also did not result in reproducible data.
Figure 2.7: TaqMan real-time PCR analysis of mRNA expression in MUTZ-LCs after
treatment with TNBS, SDS, benzylpenicillin (PenG), phenoxymethylpenicillin (PenV),
ampicillin (Amp), sulfamethoxazole (SMX) and DMSO (control) for 48h, normalized
against GAPDH. Data of 3 experiments are displayed as vertical box plot diagrams by
the Cleveland method. The median is shown as well as the 25th and 75th percentiles. The
relative RNA levels of each candidate gene are presented as x-fold regulation compared to
mRNA expression of the analyzed gene regulation in untreated cells (medium) except for
SMX, where regulation is compared to the gene regulation of DMSO-stimulated cells.
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Figure 2.8: TaqMan real-time PCR analysis of mRNA expression in MUTZ-LCs after
treatment with TNBS, SDS, benzylpenicillin (PenG), phenoxymethylpenicillin (PenV),
ampicillin (Amp), sulfamethoxazole (SMX) and DMSO (control) for 48h, normalized
against GAPDH. Data of 3 experiments are displayed as vertical box plot diagrams by
the Cleveland method. The median is shown as well as the 25th and 75th percentiles. The
relative RNA levels of each candidate gene are presented as x-fold regulation compared to
mRNA expression of the analyzed gene regulation in untreated cells (medium) except for
SMX, where regulation is compared to the gene regulation of DMSO-stimulated cells.
In summary, benzylpenicillin and phenoxymethylpenicillin were recognized as
sensitizing compounds because they are capable of inducing the mRNA ex-
pression of all marker genes in moDCs and, except for IL-8, in THP-1 cells
but not in MUTZ-LC. Ampicillin stimulated the expression of some marker
genes in moDCs and THP-1 cells. SMX did not affect the expression of these
genes in THP-1, however, in moDCs, only PIR was enhanced and there was
an increase of the release of IL-8.
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2.2 Molecular characterization and function of the human or-
ganic anion transporting polypeptide OATP5A1
OATP5A1 has been shown to be widely distributed in many cancerous tissues. High
mRNA levels were detected in normal tissues of brain, heart, skeletal muscle, ovary
[105], and breast [160]. Additionally, we found that human SLCO5A1 is highly
expressed in dendritic cells, which are key players in the regulation of immune re-
sponses. According to other OATP family members, OATP5A1 might play a role
in adverse drug reactions as well as in tumorigenesis and progression by controlling
the effect of endogenous stimuli on cell proliferation and differentiation [146]. Still,
substrates have not been identified, and protein expression and function has not been
thoroughly characterized so far. One of the main reasons is the lack of a suitable
commercially available antibody. For this reason, protein tags were attached to hu-
man OATP5A1. This should allow the molecular characterization of the transporter
polypeptide expressed in two expression systems - genetically modified Hela cells
(‘FlpIn T-Rex Hela’ cells, hereinafter referred to as Hela cells) and oocytes of Xeno-
pus laevis. To further investigate the function of OATP5A1, proliferation assays, a
global gene expression assay and transport studies were carried out.
2.2.1 Transcriptional SLCO5A1/Slco5A1 expression in tissues, primary cells
and cell lines
Primary blood cells
Messenger RNA expression of hSLCO5A1 in immature and mature dendritic cells,
as well as in progenitor cells of dendritic cells, revealed a statistically significant
expression of hSLCO5A1 mRNA in peripheral blood mononuclear cells (PBMCs),
monocytes, immature dendritic cells (iDCs) and mature dendritic cells (mDCs) as
compared to macrophages, cells which only show a very low mRNA expression of
hSLCO5A1 (fig. 2.9). Interestingly, hSLCO5A1 expression strongly increased during
differentiation from monocytes to mature dendritic cells but decreased during dif-
ferentiation from monocytes to macrophages. Expression of hSLCO5A1 in PBMCs
and monocytes did not differ by statistical significance from the expression in iDCs.
Because TNBS was found to affect the expression of cytokines, metabolic enzymes
and transcription factors, its influence was also analyzed on hSLCO5A1 expression
in moDCs. Fig. 2.10 demonstrates that TNBS significantly decreased hSLCO5A1
expression.
Although individual members of OATPs in human and rodents are not derived
from complete orthologous genes, mouse Slco5A1 expression was also studied in im-
mature and mature LPS-dendritic cells (fig. 2.11) (provided from the Institute of
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Figure 2.9: Expression of hSLCO5A1 mRNA in primary blood cells. Human
SLCO5A1 expression, measured by qRT-PCR, is shown as mean and standard deviation of
4 different blood donors, normalized to GAPDH mRNA expression. Total RNA expression
is presented as x-fold regulation compared to hSLCO5A1 expression of the macrophage
sample from blood donor I (=1) (Avg Ct = 34,7) (PBMC: peripheral blood mononuclear
cells, iDC: immature dendritic cells, mDC: mature dendritic cells). *p<0,05; **p<0,005.
Figure 2.10: Human SLCO5A1 mRNA expression of moDCs treated with TNBS.
moDCs isolated from buffy-coats of 5 blood-donors were treated with 200 µg/ml TNBS
for 48h. Total RNA expression is presented as x-fold down-regulation compared to
hSLCO5A1 expression of unstimulated moDCs (=1). RNA expression is normalized to
GAPDH mRNA expression. **p<0,005.
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Figure 2.11: Expression of mouse Slco5A1 mRNA in dendritic cells (DCs). Slco5A1
expression, measured by qRT-PCR, was normalized to mGAPDH mRNA expression. Data
are displayed as average Ct-values. DCs were isolated from murine bone-marrow. To in-
duce maturation of immature DCs, cells were stimulated with 10 ng/ml Lipopolysaccha-
ride (LPS-DCs).
Cell Biology, University Hospital RWTH Aachen). Mouse iDCs exhibited a lower
average Ct-value (∼29) than human iDCs (∼25). In contrast to human DCs where
hSLCO5A1 mRNA expression increased during maturation of DCs, mouse Slco5A1
mRNA expression decreased during maturation. Mouse mDCs (LPS-DCs) exhibited
an average Ct-value of ∼31 in contrast to human mDCs with an average Ct-value
of ∼22. These data indicate that human SLCO5A1 expression is not comparable to
mouse Slco5A1 expression.
Normal and cancerous tissue, primary cells and cell lines of human skin
To find out if SLCO5A1 is expressed in human skin and in skin-related cancer, mRNA
expression of SLCO5A1 was analyzed in skin tissue samples and skin cells as well as
in squamous cell carcinoma tissue and melanoma cell lines using qRT-PCR.
In contrast to primary blood cells, skin tissue and cells displayed a weak SLCO5A1
expression (fig. 2.12A). Primary keratinocytes, fibroblasts and melanocytes showed
an average Ct-value of ∼32. SLCO5A1 mRNA expression differed between squa-
mous cell carcinoma samples (SCC), a major form of skin cancer. The samples
SCC13 and SCCA2 showed a higher SLCO5A1 mRNA expression when compared
to non-cancerous epidermis/dermis.
On the other hand, some melanoma cell lines showed an increased SLCO5A1 expres-
sion (fig. 2.12B). Such high SLCO5A1 expression was found in the melanoma cell lines
Mel-Juso, Mel-Ho, G-361, SK-MEL-5 and SK-MEL-30 but not in SK-MEL-24 and
SK-MEL-31. SLCO5A1 expression of the melanoma cell lines Mel-Juso, G-361 and
SK-MEL-5 is comparable to transporter expression in primary monocytes (fig. 2.9).
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Figure 2.12: Expression of SLCO5A1 mRNA in skin tissue/ cells (A) and in melanoma
cell lines (B).
A) SLCO5A1 expression was measured by qRT-PCR, and normalized to HPRT mRNA
expression. Data are presented as average Ct-values. Numbers are referring to donors.
SCC: squamous cell carcinoma.
B) SLCO5A1 expression was measured by qRT-PCR, and normalized to 18S mRNA ex-
pression. Data are presented as x-fold regulation compared to SLCO5A1 expression of the
PHM (primary human macrophage) sample (=1) (Avg Ct = 33).
2.2.2 Molecular characterization of human OATP5A1 in Hela cells
For the characterization of human OATP5A1 protein, Hela cells were stably ex-
pressed with human wild-type (WT) and mutant OATP5A1. Mutant OATP5A1
contains a single nucleotide polymorphism (SNP) on amino acid 33 where Leucine
(L) is mutated to phenylalanine (F) (see materials and methods). According to
UniprotKB (ref. seq. Q9H2Y9) this sequence corresponds to a natural variation
(VAR_022041), and it emerged as a cloning result using cDNA from primary moDCs
as PCR-template. This sequence variation could occur because of human blood-
donor-variability. It is still unclear whether this variation has effects on protein ex-
pression and functional properties. Due to the lack of a suitable antibody, the protein
sequences were modified by C-terminal insertion of either a HA-tag (haemagglutinin)
(1 kDa) or a YFP-tag (yellow-fluorescent protein) (27 kDa). Protein expression was
induced with Tetracycline (tet).
Stable OATP5A1-HA-expressing Hela cell clones
Seven WT clones and six mutant clones were selected showing different gene and
protein expression (fig. 2.13). For both WT and mutant, the amount of mRNA
expression correlated with the amount of protein expression. Messenger RNA and
protein expression of the WT and mutant was well detectable in all cell clones except
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for clone 5 (WT) and clone 4 (mutant). The strongest WT expression could be
detected with the cell clones 1 and 6. The strongest mutant expression could be
detected with the cell clones 1, 2 and 5. Although tetracycline/doxycycline-reduced
FCS was used for cell culture, a low basal expression of SLCO5A1-HA could be
observed even without tet.
Figure 2.13: mRNA (A/B) and protein (C/D) expression of wild-type (WT) and mu-
tant (L33F) hSLCO5A1-/hOATP5A1-HA-expressing Hela cell clones. mRNA and pro-
tein expression was measured after 48h treatment with 1 µg/ml tetracycline.
A/B) Human SLCO5A1 expression was measured by TaqMan qRT-PCR, and was normal-
ized to GAPDH mRNA expression. Relative RNA levels are presented as x-fold regulation
compared to hSLCO5A1 expression in untransfected Hela cells (= 1). As a basal mRNA
expression control, cells were left untreated.
C/D) Human OATP5A1 expression was determined by western blot analysis using an anti-
HA antibody. Tubulin served as loading control.
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Additionally, stable mock-Hela clones were prepared as control cells. To this effect,
Hela cells were transfected with the plasmid backbone pcDNA5/FRT/TO. Six stable
mock-Hela-clones were selected (fig. 2.14). Clone 3 and clone 6 were used for further
studies.
Figure 2.14: mRNA expression of stable mock Hela clones. The relative hSLCO5A1
mRNA levels, measured by TaqMan qRT-PCR and normalized to GAPDH mRNA expres-
sion, are presented as x-fold regulation compared to hSLCO5A1 expression in untrans-
fected Hela cells (= 1).
Inducible expression of OATP5A1-HA with Tetracycline
To detect the concentration of tet needed for subsequent expression of WT and
mutant SLCO5A1-HA/OATP5A1-HA, stable cells of WT clone 1 and mutant clone
1 were incubated with a concentration-range of 0-1 µg/ml tet (fig. 2.15). As observed
for WT and mutant OATP5A1, a concentration of 0,05 µg/ml tet is already sufficient
for RNA and protein expression (fig. 2.15 B/D). Higher concentrations of tet did not
significantly alter both mRNA and protein expression. No significant differences
between WT and mutant OATP5A1-HA could be observed.
Exclusion of apoptosis using an anti-PARP antibody
Two stable Hela clones with the highest protein expression for WT and mutant
OATP5A1-HA were used for further studies. Using an anti-HA antibody, two pro-
tein bands of approximately 105 kDa and 130 kDa could be detected for both WT
and mutant OATP5A1 (fig. 2.16A).
To exclude possible cytotoxic effects of tet, western blot analysis was performed using
an anti-PARP antibody, which recognizes the 113 kDa full-length variant of Poly-
ADP-Ribose-Polymerase (PARP), as well as the 89 kDa PARP fragment cleaved by
proteases. Detection of the 89 kDa PARP fragment with anti-PARP serves as an
early marker of apoptosis. As seen in fig. 2.16B, the 113 kDa PARP bands but
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not the 89 kDa cleaved fragments could be detected after inducible protein expres-
sion compared to untreated Hela clones neither for WT OATP5A1 nor for mutant
OATP5A1. Data clearly showed no apoptosis.
Figure 2.15: mRNA and protein expression of wild-type (WT) (A/B) and mutant
(L33F) (C/D) hSLCO5A1-/hOATP5A1-HA expressing Hela cell clones stimulated
with 0,05 to 1 µg/ml tetracycline for 24h.
A/C) The relative mRNA levels, measured by TaqMan qRT-PCR and normalized to
GAPDH mRNA expression, are presented as x-fold regulation compared to hSLCO5A1
expression in untreated Hela cells (= 1).
B/D) Human OATP5A1 expression was determined by western blot analysis using an anti-
HA antibody. Tubulin served as loading control.
Figure 2.16: Western blot analysis of HA (A) and PARP (B) in wild-type (WT) and
mutant (L33F) hOATP5A1-HA expressing Hela cell clones. Hela cell clones were
treated with 1 µg/ml tetracycline for 48h. Tubulin served as loading control.
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Primary antibodies against OATP5A1
To demonstrate the unspecificity of anti-OATP5A1 antibodies, WT and mutant
OATP5A1-HA clones were targeted with primary antibodies from two different com-
panies (see chapter 4 ‘materials and methods’) in the absence and presence of
1 µg/ml tet. Fig. 2.17A shows the detection of OATP5A1-HA with a recombinant
OATP5A1 antibody (E. coli) ordered from AbD-Serotec. Fig. 2.17B shows the detec-
tion of OATP5A1-HA with an OATP5A1-antibody from Abcam (polyclonal, rabbit).
The protein bands of approximately 105 kDa and 130 kDa stained with anti-HA-
antibody were not observed using both OATP5A1-antibodies. Although a protein
band of 130 kDa could be detected with the OATP5A1-antibody from AbD-Serotec,
a stronger expression of OATP5A1 after induction with tet in contrast to untreated
cells could not be observed.
Figure 2.17: Western blot analysis of wild-type (WT) and mutant (L33F) hOATP5A1
using antibodies from AbD-Serotec (A) and Abcam (B). Human OATP5A1-HA-
expressing Hela cell clones were treated with or without 1 µg/ml tetracycline for 48h.
Tubulin served as loading control.
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Deglycosylation of OATP5A1-HA with EndoH and PNGaseF
To analyze whether the observed OATP5A1 double band corresponds to the core-
and complex-glycosylated protein variants, WT and mutant OATP5A1-HA were
deglycosylated using the endoglycosidases EndoH (E) and PNGaseF (P) (fig. 2.18).
EndoH removes high mannose-type sugars specific for proteins that have not yet left
the ER, whereas PNGaseF releases complex-type carbohydrates from both core- and
complex-glycosylated proteins of ER and Golgi. The HA-tag (∼1 kDa) allows the
detection of the actual OATP5A1 protein size. Without endoglycosidases a double
protein band of approximately 105 kDa and 130 kDa was detected, as described be-
fore. After deglycosylation of the samples with EndoH, a shift of the 105 kDa protein
bands to approximately 92 kDa could be observed, which corresponds to the putative
OATP5A1 protein size. After deglycosylation of the samples with PNGaseF, both
bands of 105 kDa and 130 kDa shifted to a size of 92 kDa. Figure 2.18 clearly showed
that the protein of 105 kDa represents the core-glycosylated variant of OATP5A1 and
the 130 kDa band represents the complex-glycosylated variant of OATP5A1, which
could be shown in oocytes as well (fig. 2.29). No difference between WT and mutant
OATP5A1-HA could be observed.
Figure 2.18: Western blot analysis of deglycosylated hOATP5A1-HA protein. WT or
mutant hOATP5A1-HA protein induced with tetracycline for 48h was deglycosylated with
either endoglycosidase H (EndoH) (E) or PNGase F (P). Tubulin served as loading control.
Analysis of OATP5A1-HA expression by Flow Cytometry
Additional to western blot analysis, OATP5A1-HA was also analyzed by flow cy-
tometry (fig. 2.19) using an anti-HA antibody (see ‘materials and methods’). The
topological model of OATP5A1 suggests that both N- and C-terminus are localized
intracellularly (fig. 1.5). Because the HA-tag was coupled to the C-terminus, surface
expression of OATP5A1 protein could not be distinguished from cytosolic protein ex-
pression. Thus, for the detection of total OATP5A1 expression, including surface-,
cytosolic- and other cell compartments, Hela cells were permeabilized using the sur-
factant saponin (0,03%). As expected, without saponin no OATP5A1 or very low
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basal expression of WT and mutant OATP5A1 could be detected. In the presence
of saponin, intracellular OATP5A1 protein was measurable. However, fluorescence
intensities were quite different within a cell-population and between cell clones. WT
clone 1 and mutant clone 1 exhibited a stronger fluorescence intensity than WT clone
4 and mutant clone 2.
Figure 2.19: Flow cytometric analysis of wild-type (WT) and mutant (L33F)
hOATP5A1-HA clones. Cells were treated with or without 1 µg/ml tetracycline for 48h.
Human OATP5A1 was detected in the absence or presence of 0,03 % saponin using an
AlexaFluor488-coupled anti-HA antibody.
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Stable Hela cell clones expressing OATP5A1-YFP
Additional to HA clones described before, Hela clones stably expressing OATP5A1-
YFP were constructed for cell-surface detection of OATP5A1. Fig. 2.20 shows stable
WT and mutant SLCO5A1-YFP clones with different mRNA expression.
Figure 2.20: mRNA expression of wild-type (WT) and mutant (L33F) hSLCO5A1-
YFP expressing Hela clones. mRNA expression was measured after 24h treatment with
1 µg/ml tetracycline. As a basal mRNA expression control cells were left untreated. The
relative hSLCO5A1 mRNA levels, measured by TaqMan qRT-PCR and normalized to
GAPDH mRNA expression, are presented as x-fold change compared to hSLCO5A1 ex-
pression in untransfected Hela cells (= 1).
Figure 2.21: Protein expression of wild-type (WT) and mutant (L33F) hOATP5A1-
YFP. hOATP5A1-YFP protein expression in Hela cells treated with or without 1 µg/ml
tetracycline for 48h was determined by western blot analysis using an anti-GFP antibody.
Tubulin served as loading control.
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WT clone 1 is not induced after stimulation with tet. Again, a low basal expression
of SLCO5A1-YFP could be observed even without tet. No significant differences
in the amount of mRNA expression were recognizable between cells encoding WT
SLCO5A1-YFP and mutant SLCO5A1-YFP.
Two WT and mutant clones were selected and analyzed at protein level (fig. 2.21).
OATP5A1-YFP protein of all cell clones was expressed without differences between
WT and mutant after stimulation with tet. OATP5A1-YFP was expressed as a
double band of approximately 120 kDa and 160 kDa. A further protein band was
detected at approximately 50 kDa, which could not be observed with OATP5A1-
HA-expressing Hela cells.
Confocal Fluorescence Microscopy
To localize OATP5A1 in the cell, the fluorescence of YFP from WT OATP5A1-YFP
and mutant OATP5A1-YFP was determined by confocal fluorescence microscopy
(fig. 2.22). OATP5A1 was widely expressed throughout the cell. A strong expression
was seen around the nucleus. Apart from the expression of OATP5A1 in the cyto-
plasm, the protein was also found on the plasma membrane. Apparently, OATP5A1
expression was very distinctly recognizable at the cell extensions seen especially at
the cell extensions of the WT. It is noteworthy that some of the Hela cells seemed
to express OATP5A1 in a lower amount or even not at all. Again, no significant dif-
ferences in the strength of expression and in the localization of OATP5A1 between
the WT and the variant were found.
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Figure 2.22: Confocal fluorescence microscopy. WT or mutant hOATP5A1-YFP ex-
pression after induction with 1 µg/ml tetracycline for 24h (blue: DAPI; yellow: YFP).
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2.2.3 Functional studies using Hela cells stably expressing OATP5A1
To analyze the possible role of OATP5A1 function, untagged stable SLCO5A1/OATP-
5A1-expressing Hela cell clones were created to avoid physiological changes that could
occur through protein tags.
Fig. 2.23 shows that mRNA expression of SLCO5A1 was induced in both WT and
mutant clones after stimulation with tet except for WT clone 5 and mutant clone
4. Again, a low basal expression of SLCO5A1 was observed even without tet. Some
Hela cell clones encoding mutant SLCO5A1 showed a higher mRNA expression than
WT SLCO5A1 cell clones.
Figure 2.23: mRNA expression of wild-type (WT) and mutant (L33F) hSLCO5A1-
expressing Hela clones. mRNA expression was measured after 24h treatment with
1 µg/ml tetracycline. As a basal mRNA expression control cells were left untreated. The
relative hSLCO5A1 mRNA amounts, measured by TaqMan qRT-PCR and normalized to
GAPDH mRNA expression, are presented as x-fold regulation compared to hSLCO5A1
expression in untransfected Hela cells (= 1).
Influence of SLCO5A1 gene expression on cell proliferation
The effect of SLCO5A1 on cell proliferation was studied inWT and mutant SLCO5A1-
expressing Hela cells and mock cells over a period of 96h (fig. 2.24). Interestingly,
in both WT and mutant cells, the proliferation was significantly inhibited after in-
duction of SLCO5A1 expression. Even though mutant SLCO5A1 expression did not
result in a strong inhibition, the tendency of growth inhibition was the same as seen
in the WT.
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Figure 2.24: Proliferation assay of wild-type and mutant hSLCO5A1-expressing Hela
cells. The proliferation rate of stable Hela cells was measured by counting cells incubated
in the presence or absence of tetracycline (1 µg/ml). At the indicated time points the to-
tal cell number was determined by using the Casy Counter System. Mean values with
standard deviation of 3 biological replicates are displayed (*p = 0,023).
Gene expression profiling of SLCO5A1 gene expression
To further analyze whether the expression of SLCO5A1 alone has effects on the tran-
scriptome of Hela cells, an exon gene expression assay was carried out where mock
cells were compared to WT SLCO5A1-expressing cells both treated with tet for 24h
(fig. 2.25). Genes with a fold change larger than 2.0 were analyzed. Among them,
genes were selected and clustered according to their biological function. Most of the
genes identified are involved in system- and anatomical structure development, for
example FOS, HOXB9, MMP2, ZFP42, SLC1A3, IGFBP5, TGM2, and CDH13, as
well as in cell-cell adhesion, for example CDH13, S100A16, PCDHBs and DSC3. It
is notable that some genes detected are involved in innate immune reactions, partic-
ularly in the complement activation (alternative pathway), e. g. C3, C5, and CFH.
CDH13, IGFBP5, TGM2, and TCF4 represent genes involved in smooth muscle cell
proliferation. Interestingly, the identified genes EPS8, CDH13, and SLC1A3 are
connected with the process of neuron projection and the genes MAP1B, PCDHB2,
PCDHB14, and PCDHB16 with synapse organization/synapse assembly. Genes like
OSMR, WFDC1, EPS8, TGFBI and HAS2 influence cell proliferation. Nearly all
of the genes shown in fig. 2.25 were expressed as a response to a (still unidentified)
stimulus. The complete results of this microarray experiment can be found as sup-
plemental information (table A.1).
The mRNA expression of the genes DSC3, TGM2, OSMR, CCL20, and CYP1B1
could be confirmed in WT OATP5A1 cells using qRT-PCR. SLCO5A1 expression
served as positive control (∼75-fold) (fig. 2.26).
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Figure 2.25: Analysis of gene expression using exon expression array.
RNA samples of mock Hela cells respectively Hela cells expressing wild-type SLCO5A1
treated with 1 µg/ml tetracycline for 24h were collected and analyzed on Affymetrix Exon
Arrays. Results of wild-type SLCO5A1 were compared to mock samples. Expression
values of genes with a fold-change larger than 2.0 were selected using the GeneSpringr
GX 12.0 software. Selected genes were clustered according to their biological function
(for complete results see supplemental data (table A.1)). A fold-change expression of
30,2-fold was observed for hSLCO5A1 (control) (not shown).
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Figure 2.26: Analysis of gene expression using qRT-PCR.
Confirmation of Gene Chip Human Exon 1.0 ST microarray analysis data by quantitative
real-time PCR. The expression of the indicated genes was analyzed after application of
mock Hela cells and Hela cells expressing wild-type hSLCO5A1 with 1 µg/ml tetracycline
for 24h. The relative expression levels of wild-type hSLCO5A1 were compared to mock
(= 1) and normalized to GUSB expression. Mean values with standard deviation of 3
biological replicates are displayed.
2.2.4 Molecular characterization of human OATP5A1 in X. laevis oocytes
X. laevis oocytes represent an important research tool for the investigation of mem-
brane proteins. By injecting cRNA into the oocyte, membrane protein products can
be studied in a controlled system. To this effect, wild-type (WT) and mutant (L33F)
OATP5A1 were N- or C-terminally tagged with six histidines.
Western blot of OATP5A1 from X. laevis oocyte eluates
To analyze whether the protein size of WT and mutant OATP5A1 in X. laevis
oocytes correspond to those seen in human Hela cells, western blot analysis was
performed. As shown in fig. 2.27, His-tagged OATP5A1 appeared at a molecular
weight of about 105 kDa and 45 kDa, which was clearly visible using low protein gel
loading (samples E01 and E03). Additional protein bands were seen using a higher
protein amount (samples E02 and E04).
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Figure 2.27: Western blot analysis of wild-type (WT) and mutant (L33F) OATP5A1
from X. laevis oocyte protein eluates. cRNA for WT and mutant SLCO5A1 tagged either
N- or C-terminally with six histidines was injected in X. laevis oocytes. Protein isolation
was performed by Ni-NTA-agarose chromatography. Western blot analysis was performed
using an anti-Histidine antibody.
Analysis of cell-surface and total OATP5A1 protein expression using SDS-PAGE
Wild-type (WT) and mutant (L33F) OATP5A1 encoding N- or C-terminally hex-
ahistidine tags for one-step purification, as well as the control proteins hGlyRα1-His
and mAno1-His, were expressed in X. laevis oocytes to analyze their cell-surface and
total protein expression. WT OATP5A1 (fig. 2.28, lanes 9-12) or mutant OATP5A1
(fig. 2.28, lanes 5-8) as well as the control proteins hGlyRα1 (fig. 2.28, lanes 1, 2)
and mAno1 (fig. 2.28, lanes 3, 4) were incorporated into the oocyte plasma mem-
brane, as illustrated by the IR-800 scan (upper part). To visualize the OATP5A1
variants, a ∼133-fold higher image gain setting was required compared to the control
proteins, which exhibited strong IR-800-NHS fluorescence. The OATP5A1 proteins
migrated in 4%-10% nonreducing SDS-urea-PAGE gradient gels as double bands
with a molecular mass of ∼80 kDa and ∼95 kDa (upper part, lanes 5, 7, 9, 11).
Only one band of ∼85 kDa was seen in the [35S]-scan (lower part). In their non-
reduced forms, the analyzed control proteins hGlyRα1-His and mAno1-His migrated
as 40 kDa (lane 1) and 100 kDa bands (lane 3), respectively, which is close to the
masses of their sequence predicted protein cores (39 kDa and 110 kDa) (excluding the
His-tag and carbohydrates). Reduction with DTT slightly increased the apparent
molecular mass of the proteins (lanes 2, 4, 6, 8, 10, 12). Interestingly, the protein
expression of C-terminally labeled WT and mutant OATP5A1 was stronger than the
protein expression observed with N-terminally, His-tag-labeled proteins. No differ-
ence in the amount of protein expression between WT and mutant OATP5A1 could
be observed.
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Figure 2.28: SDS-urea-PAGE analysis of wild-type (WT) and mutant (L33F) His-
tagged OATP5A1. X. laevis oocytes expressing the constructs N-His-hOATP5A1WT/L33F
or C-His-hOATP5A1WT/L33F were [35S]-methionine labeled, chased, surface-labeled with
the membrane-impermeable infrared (IR) dye 800-NHS and then extracted with digitonin.
Proteins were purified by Ni-NTA chromatography and resolved by reducing SDS-urea-
PAGE. The gel was visualized by phosphorimaging and Odyssey IR scanning to display
the total (lower parts, black) and cell-surface (upper parts, green) pools of the proteins,
respectively. A molecular-mass marker (All Blue Standard, BioRad) was electrophoresed
in parallel (red). SDS-urea-PAGE analysis was performed under non-reducing (-) and
reducing conditions (+) by adding 20 mM DTT. The proteins hGlyRα1-His (lanes 1-2) and
mAno1-His (lanes 3-4) served as expression control and molecular weight control. Lanes
5-8 represent hOATP5A1L33F and lanes 9-12 represent hOATP5A1WT. The numbers 12.00
and 1.600 represent the image gain settings used.
Deglycosylation of OATP5A1 with EndoH and PNGaseF
To analyze the glycosylation state of WT and mutant OATP5A1, proteins were
deglycosylated with EndoH (E) and PNGaseF (P) (fig. 2.29). The double bands
observed for WT and mutant OATP5A1 with IR-800-scan (fig. 2.29, upper parts)
correspond to the core- and the mature complex-glycosylated forms, respectively
(lanes 4-15), as seen also in Hela cells (fig. 2.18). Both core- and complex-glycosylated
forms of OATP5A1 (upper part, lanes 4, 7, 10, 13) reached the plasma membrane. In
contrast, only the complex-glycosylated form of the control mAno1-His reached the
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plasma membrane (upper part, lane 1), indicating efficient egress from the ER to the
Golgi and later compartments. Deglycosylation with PNGaseF reduced the average
molecular mass of OATP5A1 by ∼13 kDa to a putative protein size of 75 kDa. The
average molecular mass of mAno1-His was reduced by ∼17 kDa (lower part). Because
of the heterogeneity of complex-type carbohydrates, the mass of individual complex-
type N-glycans is unknown. Thus, their number cannot be ascertained from the size
of the mass shift [31]. As seen in the lower part, the [35S]-scan displays mainly the
core-glycosylated OATP5A1 protein.
Analysis of native cell-surface and total OATP5A1 protein expression using BN-PAGE
To determine the possible higher-order structure of OATP5A1, proteins purified un-
der native conditions were analyzed using BN-PAGE (fig. 2.30). As positive controls,
two chloride channels of known quaternary structure (the homopentameric hGlyRα1-
His) and of known homodimeric structure (mAno1-His) were coanalyzed. In addition,
hGlyRα1-His and mAno1-His, as well as their well-defined lower-ordered intermedi-
ates generated by partial denaturation, were used as reliable molecular-mass markers
for the determination of the mass of the assembled and SDS-disassembled OATP5A1
proteins. By substituting these well-defined membrane proteins for the common solu-
ble calibration proteins, the errors that arise when estimating the mass of membrane
proteins by comparison with soluble proteins are avoided [100, 159]. Non-denatured
WT (lanes 9, 12) and mutant OATP5A1 (lanes 3, 6) migrated as a single band of
∼200 kDa, displayed by IR-800-scan (upper part). [35S]-scan (lower part) exhibited
three bands of approximately 290 kDa, 208 kDa, and 155 kDa. However, the 155 kDa
band was very weak. In contrast, the non-denatured control proteins hGlyRα1-His
and mAno1-His migrated as single, well-defined oligomeric complexes of approxi-
mately 290 kDa (lower part, lanes 2, 15, 17). To determine the possible numbers
of protomers incorporated in the OATP5A1 protein, the noncovalent subunit inter-
actions were weakened by treating the natively purified, nonreduced protein with
increasing concentrations of SDS. Incubation with 0,01% to 0,1% SDS resulted in
the appearance of a faster migrating protein band (single or double band), displayed
by IR-800-scan (upper part, lanes 4, 5, 7, 8, 10, 11, 13, 14). [35S]-scan (lower part)
exhibited also a faster migrating protein band (triple band) depending on the used
SDS concentration. The speed of migration seemed to correspond with the increasing
SDS concentration. Upon a similar SDS denaturation, hGlyRα1-His disassembled
into homotetramers, homotrimers, homodimers, and protomers (lanes 1, 16), con-
sistent with their well-known homopentameric nature, and mAno1-His disassembled
into homodimers and protomers (lane 18), consistent with their well-known homod-
imeric nature.
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Figure 2.29: Deglycosylation of wild-type (WT) and mutant (L33F) His-tagged
OATP5A1. X. lavis oocytes expressing the constructs N-His-hOATP5A1WT/L33F or C-
His-hOATP5A1WT/L33F were [35S]-methionine labeled, chased, surface-labeled with the
membrane-impermeable infrared (IR) dye 800-NHS and then extracted with digitonin.
Proteins were purified by Ni-NTA chromatography and resolved by reducing SDS-urea-
PAGE. The gel was visualized by phosphorimaging and Odyssey IR scanning to display
the total (lower parts, black) and cell-surface (upper parts, green) pools of the proteins,
respectively. A molecular-mass marker (All Blue Standard, BioRad) was electrophoresed
in parallel (red). SDS-urea-PAGE analysis was performed for the investigation of the gly-
cosylation state of the OATP5A1 proteins. To this effect, samples were treated with either
endoglycosidase H (EndoH) (E) or PNGase F (P) or left untreated. The protein mAno1-
His (lanes 1-3) served as deglycosylation-control. Lanes 4-9 represent hOATP5A1L33F,
and lanes 10-15 represent hOATP5A1WT. The numbers 5.000 and 1.100 represent the
image gain settings used.
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Figure 2.30: BN-PAGE analysis of wild-type (WT) and mutant (L33F) His-tagged
hOATP5A1. X. laevis oocytes expressing the constructs N-His-hOATP5A1WT/L33F or C-
His-hOATP5A1WT/L33F were [35S]-methionine labeled, chased, surface-labeled with the
membrane-impermeable infrared (IR) dye 800-NHS and then extracted with digitonin.
Proteins were purified by Ni-NTA chromatography and resolved by BN (blue-native)-
PAGE. The gel was visualized by phosphorimaging and Odyssey IR scanning to display
the total (lower parts, black) and cell-surface (upper parts, green) pools of the proteins,
respectively. A molecular-mass marker (All Blue Standard, BioRad) was electrophoresed
in parallel (red). BN-PAGE analysis was performed to detect the oligomeric structure of
OATP5A1. Where indicated, the samples were treated with 0,01-0,1 % SDS to induce
partial dissociation of the membrane transporter complexes. The proteins hGlyRα1-His
(lanes 1-2 and 15-16) and mAno1-His (lanes 17-18) served as dissociation control for the
oligomeric protein structure. Lanes 3-8 represent hOATP5A1L33F and lanes 9-14 represent
hOATP5A1WT. The grey and orange ovals schematically illustrate the oligomeric states
(protomers to pentamers) of the partially denatured hGlyRα1-His and the native homod-
imeric and the denatured protomeric state of mAno1-His, respectively. Numbers 1, 2 and
3 refer to the three protein bands which can be observed by [35S]-scan (lower part).
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2.2.5 Transport studies of wild-type and mutant OATP5A1 in Xenopus laevis
oocytes
Because OATP5A1 was found to be expressed on the surface of X. laevis oocytes,
it was studied whether human OATP5A1 shares the transport activity of classical
substrates with other OATP family members. To this effect, oocytes were incubated
with tritium-labeled substances including [14C]sucrose, an internal leakage control,
for 30 minutes (table 2.2). Notably, none of the substrates tested were found to be
transported by hOATP5A1WT or hOATP5A1L33F.
Substrate [3H] hOATP5A1 hOATP5A1 control OATPs which transport substrates
WT L33F [38]
Arachidonic acid 1074 ± 133 1091 ± 18 1439 ± 168 OATP3A1_v2
Prostaglandin E2 ND 261 ± 46 225 ± 21 OATP1A2; OATP1B1; OATP2B1;
OATP3A1_v1; OATP3A1_v2;
OATP4A1
Estrone-3-sulfate ND 118 ± 55 89 ± 51 OATP1A2; OATP1B1; OATP1B3;
OATP1C1; OATP2B1; OATP3A1_v1;
OATP4A1
Estradiol-17β-D- 157 ± 6 174 ± 34 143 ± 15 OATP1A2; OATP1B1; OATP1B3;
glucoronide OATP1C1; OATP4A1
Dehydroepiandrosterone- 102 ± 17 101 ± 10 82 ± 19 OATP1A2; OATP1B1; OATP1B3;
3-sulfate (DHEAS) OATP2B1
D-Penicillamine2,5- ND 52 ± 22 20 ± 4 OATP1A2; OATP1B1; OATP1B3
enkephalin (DPDPE)
Ouabain 129 ± 55 137 ± 61 112 ± 31 OATP1A2; OATP1B3; OATP4C1
Taurocholic acid ND 23 ± 15 11 ± 2 OATP1A2; OATP1B1; OATP1B3;
OATP2B1; OATP4A1
Benzylpenicillin 249 ± 59 272 ± 66 319 ± 41 OATP1B1; OATP2B1; OATP3A1_v1;
OATP4A1
Methotrexate ND 95 ± 48 62 ± 11 OATP1A2; OATP1B1; OATP1B3;
OATP4C1
Digoxin ND 32 ± 17 25 ± 7 OATP1B3; OATP4C1
Leukotriene C4 ND 189 ± 9 159 ± 12 OATP1B1; OATP1B3
Table 2.2: Transport assay of hOATP5A1 with Tritium-labeled substrates in Xeno-
pus laevis oocytes. The table displays the tritium-labeled substrates used for transport
assay in X. laevis oocytes (8-12 oocytes) injected with pNKS4-hSLCO5A1WT (wild-type),
pNKS4-hSLCO5A1L33F, or with the control (Tris-HCl). Oocytes were incubated with
1 µCi/ml Tritium-labeled substrate and 0,04 µCi/ml [14C]sucrose at room temperature for
30 minutes. [14C]sucrose served as internal leakage control. Radioactivity was measured
using a Beckman scintillation counter. Displayed are mean CPM (counts per minute) val-
ues with standard deviation.
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In summary, OATP5A1 data revealed that SLCO5A1 expression correlates
with the differentiation status of primary blood cells and that SLCO5A1 ex-
pression is increased in melanoma cell lines. The contact sensitizer TNBS
decreased SLCO5A1 expression in moDCs. Molecular analysis of OATP5A1
identified core- and complex-glycosylated OATP5A1 of WT and mutant in
the cytosol/ in intracellular membranes and on the plasma membrane of Hela
cells and X. laevis oocytes. A different protein size of OATP5A1 could be
observed between Hela cells and X. laevis oocytes. BN-PAGE analysis re-
vealed no evidence regarding an OATP5A1 multimer. Transport studies with
various OATP substrates could not identify any of these classical substrates
as target for OATP5A1. Inducible expression of OATP5A1 inhibited cell pro-
liferation in Hela cells. Gene expression profiling with these cells identified
genes that are involved in system- and anatomical structure development, in
cell-cell adhesion, in cell proliferation, in innate immune reactions, in smooth
muscle cell proliferation, and in the process of neuron projection and synapse
organization/synapse assembly. A single nucleotide polymorphism (SNP) of
amino acid 33 (L→F) revealed no differences regarding protein expression and
function.
3. Discussion
3.1 Sensibilization of antigen-presenting cells (APCs) by low-
molecular weight drugs
Allergic contact dermatitis and drug allergy have in common that they are mostly
induced by low-molecular weight compounds. The first part of this thesis evaluated
whether novel in vitro assays developed to detect the sensitizing potential of contact
sensitizers are suitable to measure the sensitization potential of antibiotics and to
compare three different antigen presenting experimental cell systems.
Previous studies from several laboratories, including our own, propose the use of
monocyte-derived dendritic cells (moDCs) and THP-1 cells and, furthermore, of U937
cells and MUTZ-3 cells as tools for discriminating contact sensitizers from irritants
[14, 115, 109, 6, 111, 11, 36]. Ott et al. [109] and Python et al. [115] have identified
several marker genes up-regulated after stimulation of moDCs with the known con-
tact sensitizer cinnamic aldehyde by microarray analysis [115, 109]. Their analysis
revealed genes coding for enzymes involved in xenobiotic metabolism (CES1, NQO1,
GCLM), for cytokines involved in cell activation (IL-8 and IL-1β) and for transcrip-
tion factors involved in differentiation (PIR and TRIM16). Therefore, we exposed
here THP-1 cells, moDCs and MUTZ-LCs to the beta-lactam antibiotics benzylpeni-
cillin (PenG), phenoxymethylpenicillin (PenV), ampicillin and the sulphonamide sul-
famethoxazole (SMX), and analyzed the expression of genes mentioned above. The
β-lactam-antibiotics were investigated due to the fact that, in daily clinical practice,
they are most often involved in drug allergic reactions. Additionally, sulphonamides
were included, because they also quite frequently lead to drug allergic reactions, but,
unlike betalactams, they are transformed by xenobiotica-metabolizing enzymes, and
it has been shown that the respective metabolite is the nominative antigen [128].
Intriguingly, Sieben et al. [139] showed that multiple cytochrome P450 (CYP450)
isoenzymes are expressed in moDCs. In case the prohapten is a substrate of these
enzymes, this might be the critical location where the hapten is formed.
Results of the first part of this thesis clearly show that THP-1 cells and moDCs re-
acted similarly with regard to their marker gene expression capacity after stimulation
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with antibiotics with the exception of IL-8. IL-8 gene expression is stimulated by
antibiotics in moDCs but not in THP-1 cells. In addition, IL-8 represents an appro-
priate marker in moDCs because it is expressed both on mRNA and also on the pro-
tein level. These data suggest that the applied cell systems are different with regard
to their sensitivity with moDCs being the most sensitive one. The observed differ-
ences in gene expression between the penicillins studied may be due to their different
binding capacities to plasma proteins (benzylpenicillin: 50%; phenoxymethypeni-
cillin: 80%; ampicillin: 20%). In agreement with the higher sensitivity of moDCs,
TNBS, a strong contact allergen which we used as a control, is not able to induce
IL-1β upregulation in THP-1 cells but in moDCs. In contrast, PenG and PenV were
able to enhance IL-1β mRNA expression both in THP-1 cells and moDCs. Thus,
substances such as contact allergens and antibiotics react differently according to
the cell type and the marker gene studied. With the exception of PIR, SMX did
not induce gene expression of the studied marker genes. These results support the
assumption that SMX reacts as pro-hapten which is not metabolized to its active
derivative being, therefore, not able to induce gene expression of DC activation.
Taken together, the marker genes CES1, NQO1, GCLM, TRIM16, IL-8 and IL-1β
seem appropriate for the assessment of the sensitization potential of antibiotics in
primary human cells such as moDCs that are close to in vivo conditions. Yet, human
THP-1 cells are more readily available and easier to cultivate than precursor-derived
DCs and, therefore, could be used for larger-scale studies. Moreover, the results
indicate that the marker genes NQO1, GCLM, TRIM16 and IL-1β are most suitable
for studying the sensitization potential of antibiotics in THP-1 cells.
MUTZ-3 cells have been proposed as a human myeloid cell line for distinguishing
sensitizers from non-sensitizers [115, 111, 11]. Results have shown that, due to their
different behaviour in regulation of the selected marker genes, MUTZ-LCs cannot
be considered suitable for the detection of the sensitization potential of antibiotics.
This is mainly due to the fact that MUTZ-LCs have to be derived from MUTZ-
3 cells and during this period cells undergo rapid growth before getting differen-
tiated. The MUTZ-3 cell line consists of three subpopulations: the proliferating
CD34+/CD11b- cells, the intermediate CD34-/CD14-/CD11b+ precursor cells and
the non-proliferating CD14+/CD11b+ DC precursors. In the presence of GM-CSF,
TNF-α and TGF-β MUTZ-3 cells differentiate into MUTZ-Langerhans cells (MUTZ-
LCs) [129]. Probably not all cells from the MUTZ-3 progenitor pool are differentiated
into MUTZ-LCs.
Several laboratories including our own have shown that IL-8 is a chemokine involved
in contact hypersensitivity. Thus, IL-8 represents a reliable marker gene for the iden-
tification of skin sensitizers [115, 109, 111, 110, 82, 16]. IL-1β is also an important
mediator of inflammatory reactions. It has been shown that IL-1β is expressed after
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treatment of CHS-mice with different contact sensitizers [69]. Furthermore, we could
show that genes involved in oxidative and metabolic stress-associated pathways are
involved in the sensitization reaction of beta-lactam antibiotics. GCLM and NQO1
are phase II detoxifying enzymes and antioxidant response element (ARE) –depen-
dent genes regulated by the transcription factor Nrf2 through the Keap1-Nrf2-ARE
signaling pathway. This regulatory pathway plays a major role in protecting the
cell against the toxic effects of oxidative and electrophilic stresses [115]. NQO1 is
upregulated after UVB irradiation of the skin and the formation of reactive oxygen
species, and Nrf2 establishes a glutathione-mediated gradient of UVB cytoprotection
in the epidermis [130]. Challenging the skin with allergenic and non-allergenic nitro-
halobenzenes resulted in the finding that NQO1 could act as a prohapten-activating
enzyme [134]. Carboxylesterase-1 (CES1), encoding a phase I metabolizing enzyme,
was also identified as a gene regulated by Nrf2 and is under the control of Keap-1-
Nrf2-ARE regulatory pathway [115, 148]. It could be shown that the ARE-dependent
regulation could be used as a new in vitro method for identifying chemical sensitiz-
ers combining peptide binding with ARE/EpRE-mediated gene expression in human
skin cells [81]. Interestingly, IL-8 was also shown to be up-regulated by the activation
of the transcription factor Nrf2 [165].
Moreover, transcriptional regulation processes seem to be involved in the sensitiza-
tion process of beta-lactam antibiotics. The tripartite-motif containing protein 16
(TRIM16) interacts over his RFP domain with the p10 and p20 subunit of caspase-1,
with pro IL-1β and with the NACHT domain of NALP1 and enhances IL-1β cytokine
secretion [93].
In addition to the identified marker genes for measuring the sensitization of beta-
lactam antibiotics, Gildea et al. [36] have demonstrated that benzylpenicillin (12,5mM
∼4,5mg/ml) up-regulates the genes Notch-3 (membrane protein involved in intercel-
lular signaling) and AKR1C2 (aldo-keto reductase family 1, member C2 involved
in xenobiotic metabolism) and down-regulates the genes for ABCA6 (ATP-binding
cassette, subfamily A, member 6, membrane transporter) and SLAM (signaling lym-
phocytic activation molecule) after exposure of PBMC-DCs for 24h.
Prohaptens need prior activation to become sensitizing. This activation process can
occur by the xenobiotic-metabolizing CYP450 enzymes. In our group it has been
shown that DCs express cell-type specific CYP450-dependent enzymes [13]. Fur-
thermore, our group showed that the prohapten carvoxime acts as an inducer of
p450 1B1 in human moDCs and is able to mediate a transcriptional gene expression
change of IL-8 [108]. Although DCs have metabolic capacities, results of this thesis
have shown that the prohapten SMX is not able to induce gene expression of DC
activation. Sanderson et al. [128] have shown that the enzymes CYP2C9, CYP2C8
and myeloperoxidase catalyze the conversion of SMX to an unstable hydroxylamine
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(SMX-NHOH) that auto-oxidizes to a protein-reactive nitroso metabolite (SMX-
NO). But those enzymes are hardly expressed in DCs [128, 139, 13]. Thus, the
individual metabolism route seems to be necessary for the detection of prohaptens.
Therefore, in vitro cell systems are limited regarding the detection of the sensitiz-
ing potential of prohaptens unless they are not combined with an appropriate drug
metabolizing system, such as CYP450 cocktails [16].
3.2 Transcriptional SLCO5A1/Slco5A1 expression in tissues, pri-
mary cells and cell lines
The transcriptional expression of SLCO transporters SLCO1A2, SLCO1B1, SLCO2B1,
SLCO3A4 and SLCO4A1 in primary human APCs was first described by Skazik et al.
[140]. Researchers found that SLCO2B1, SLCO3A4 and SLCO4A1 are differentially
expressed in monocytes, monocyte-derived macrophages and monocyte-derived ma-
ture dendritic cells. Interestingly, Skazik et al. [140] observed that SLCO4A1 is
highly expressed in macrophages compared to monocytes. On the other hand, ma-
ture dendritic cells showed a lower SLCO4A1 expression compared to monocytes. In
the second part of this thesis the transcriptional expression of SLCO5A1 was also
studied in human primary blood cells. Data showed that SLCO5A1 expression is
decreased during differentiation from monocytes to macrophages but is increased
during differentiation from monocytes to mature dendritic cells. Results from Skazik
et al. [140] and from this thesis suggest that the differential expression of SLCO
transporters might play a role in the differentiation process of APCs.
In the first part of this thesis it was shown that the strong contact sensitizer TNBS
increased the expression of cytokines like IL-8 and IL-1β in APCs. But TNBS also
decreased the expression of SLCO5A1 mRNA in moDCs. In mouse models it could
be shown that IL-1β reduced Slco1 and Slco2 mRNA expression in the liver [42].
In human hepatocytes mRNA levels of SLCO1B1, SLCO1B3, and SLCO2B1 were
reduced by IL-1β. This cytokine also reduced OATP1B1 protein [70]. Thus, cytokine
expression in moDCs could possibly result in an inhibition of transporter expression
and may prevent high intracellular accumulation of TNBS.
Expression of Slco5A1 in mouse DCs differs from the expression observed in human
DCs. Individual members of OATPs/Oatps in human and rodents are not derived
from complete orthologous genes. Although OATP5A1 is the only OATP family
member that contains single members of rat and mouse [40], rat and mouse Slco5A1
may not reflect the same cell distribution as human SLCO5A1. Furthermore, mouse
and human DCs have been generated from different progenitor cells. Mouse DCs
have been generated from CD34+ precursors obtained from bone marrow, whereas
human DCs have been derived from peripheral blood mononuclear cells (PBMCs).
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Human solute carrier transporter SLCO5A1/OATP5A1 was described to be ex-
pressed in many cancerous tissues. Data of this thesis show that SLCO5A1 is also
strongly expressed in melanoma cell lines derived from skin. But only low expression
of SLCO5A1 could be identified in primary melanocytes, keratinocytes and fibrob-
lasts. OATP-D (OATP3A1) was also found to be expressed in melanoma G361 cells
[4]. Export transporters such as MRPs are expressed in malignant melanoma [158].
The ABC transporter 5 was identified in 11% of primary melanocytes and 3% of
melanoma cells [32]. Several human ABC proteins showed a high mRNA expression
profile in melanoma in comparison to normal melanocytes [43]. MMPs (matrix met-
allopeptidases), cadherins, integrins and TGF-β are relevant molecules in melanoma
development. The most basic process underlying cancer invasion and metastasis is a
dynamic actomyosin cytoskeleton that in response to external factors drives cell po-
larity, turnover of cell-matrix interactions, and migration of cancer cells away from
the primary lesion into surrounding tissues, blood, and lymph vasculature. This
process includes signaling molecules, cell adhesion molecules, and molecules for cell
architecture [64]. Genes encoding such molecules could be identified via microarray
analysis after SLCO5A1 expression in Hela cells.
3.3 Molecular characterization of human OATP5A1
3.3.1 Hela cells
Although OATP5A1 protein has been detected in many cancerous tissues, so far, the
molecular characterization of OATP5A1 protein expression has not been further stud-
ied. Therefore, OATP5A1 protein expression was investigated using stable inducible
Hela cells. A very low amount of SLCO5A1 gene expression for the various constructs
could be detected even without tetracycline compared to untransfected Hela cells.
It suggests that the Tet repressor may not have bound completely to the promoter
region of pcDNA5/FRT/TO in all Hela cells or, more likely, that a remaining quan-
tity of tetracycline/doxycycline in the medium (although tetracycline/doxycycline-
reduced FCS was used) already induced SLCO5A1 expression. In contrast, endoge-
nous expression of OATP5A1-HA/-YFP protein could not be observed.
WT and mutant OATP5A1-HA protein was expressed as a double band with a
molecular mass of approximately 105 kDa and 130 kDa. OATP5A1-YFP variants
were also expressed as a double band of approximately 120 kDa and 160 kDa which
is similar to the protein size observed with OATP5A1-HA excluding the YFP-tag
of ∼27 kDa. In contrast to OATP5A1-HA, a further protein band of approximately
50 kDa was detected for OATP5A1-YFP. The formation of this band remains un-
clear. Dose-dependency of inducible OATP5A1-HA expression with tetracycline
was not detectable, but it appeared that the concentration of 1 µg/ml revealed the
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best results for confocal fluorescence microscopy. Flow cytometric analysis of WT
and mutant OATP5A1-HA expression could not distinguish between cell-surface
and intracellular localization of the transporter polypeptide due to the intracellu-
lar C-terminally labeled HA-tag. Depending on the analyzed Hela clones, different
amounts of OATP5A1 expression could be detected as observed also by western blot
analysis. Quite wide histogram peaks indicate that Hela cells stained positive or less
positively resulted in different fluorescence intensities, thus, reflect different amounts
of OATP5A1-HA expression within a cell clone population as observed also by con-
focal fluorescence microscopy. The reason for this might be that cells are at different
stages of the cell-cycle.
Deglycosylation of OATP5A1-HA resulted in the putative protein size with a molec-
ular mass of ∼92 kDa. The observed double band corresponds to the core- and
complex-glycosylated OATP5A1 protein. According to the topological model, pu-
tative N-glycosylation sites could be located on asparagine residues of extracellular
loop two and five at positions 228, 241, 550, 590, 597 and 730 (fig. 1.5). It is assumed
that posttranslational modification by N-glycosylation is important for OATPs be-
cause it seems that this modification is responsible for both its functional activity
and its delivery to the cell membrane [73].
Confocal fluorescence microscopy of WT and mutant OATP5A1-YFP revealed both
an expression of OATP5A1 in the cytoplasm/ in intracellular membranes and on the
cell surface of Hela cells. Although OATPs are usually expressed on cell membranes,
strong cytoplasmic staining was also seen for both OATP1A2 in breast cancer and
OATP1B3 in colon cancer [104]. Only partial expression of OATP5A1 on the plasma
membrane of Hela cells could result from aberrant posttranslational regulation such
as phosphorylation, which, for instance, regulates the cell surface expression of human
OATP2B1 [59]. Membrane OATP5A1 expression was very distinctly recognizable at
the cell extensions of Hela cells. This observation and the finding that SLCO5A1
expression correlates with the expression of cell adhesion molecules identified by mi-
croarray analysis suggest that OATP5A1 might be involved in the process of cell
adhesion. Noteworthy, some of the Hela cells expressed OATP5A1-YFP in a lower
amount or even not at all. Partly, this could be due to the focus layer. But most
likely, OATP5A1-YFP expression may vary according to the cell-cycle.
The natural variant L33F of OATP5A1 in comparison to WT OATP5A1 showed
no differences regarding their molecular characterization. Nevertheless, variations in
genes encoding uptake transporters can cause effects on the expression in cells and
can cause interindividual variations of drug effects [62].
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3.3.2 Xenopus laevis oocytes
OATP5A1 protein expression was also investigated in X. laevis oocytes. Western
blot analysis using an anti-Histidine antibody revealed two significant protein bands
at approximately 105 and 45 kDa. Samples of C-terminally His-tagged WT and
mutant OATP5A1 revealed six protein bands at approximately 200, 125, 105, 75,
60, and 45 kDa in contrast to N-terminally His-tagged WT and mutant OATP5A1,
which is due to the different amount of eluate loaded onto the gel. His-tag purifica-
tion results not only in the elution of His-tagged OATP5A1 but also in the elution
of proteins which contain several histidines. This may explain the variety of protein
bands observed.
Data of SDS-PAGE clearly show that WT and mutant OATP5A1 are expressed
on the cell surface of oocytes both as core- and complex-glysosylated forms with a
molecular mass of ∼80 kDa and ∼95 kDa, respectively, as displayed by IR-800-scan.
The [35S]-scan revealed that mainly the core-glycosylated protein can be recognized
in the cytosol. The staining of cell-surface proteins with IR-800-NHS dye is more
sensitive than the labeling of cytosolic proteins with 35S. Binding of IR-800-NHS dye
to only one or two lysines is already sufficient for a good visualization of weak protein
bands by IR-scanning, whereas weak protein bands of 35S-labeled proteins exhibit a
lower signal intensity after scanning on a Phosphor-Imager. The different intensities
of protein bands observed can be correlated to the different protein expression lev-
els between N- and C-terminal His-tagged OATP5A1. The low fluorescence of the
OATP5A1 variants compared to control proteins hGlyRα1-His and mAno1-His may
reflect less efficient incorporation of the proteins into the plasma membrane and/or
a lower number of cell-surface exposed lysine residues that were accessible for the
labeling reaction. The protein shift observed with DTT may be a result of the reduc-
tion of intrasubunit disulfide bonds. Deglycosylation of OATP5A1 resulted in the
putative protein size with a molecular mass of ∼75 kDa. The discrepancy between the
observed putative protein sizes in X. laevis oocytes and Hela cells could be due to the
expression of the full-length variant of OATP5A1 in Hela cells (848 aa/92 kDa) and
of the transcript variant OATP5A1 isoform 2 (687 aa/75 kDa) in X. laevis oocytes.
Destabilizing denaturation of native OATP5A1 in BN-PAGE with SDS led to a faster
migrating double or triple band, while chemical reduction with DTT did not (data
not shown), indicating that mainly non-covalent interactions are responsible for the
formation of the native OATP5A1 protein structure. Although OATP5A1 bands are
shifting in the presence of SDS, the comparison of OATP5A1 with the denatured
states of mAno1-His and hGlyRα1-His indicates that OATP5A1 is a monomer. A
crosslinking experiment with glutaraldehyde supports this finding (data not shown).
Again, WT and mutant OATP5A1 showed no differences regarding their molecular
characterization.
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3.4 Functional studies of human OATP5A1 in X. laevis oocytes
and Hela cells
3.4.1 Transport studies
Transport assays performed in X. laevis oocytes could not identify any of the sub-
stances tested as substrate for WT or mutant OATP5A1. Although OATP5A1 was
expressed on the cell surface of oocytes, it is unclear if the protein was function-
ally active. Perhaps, OATP5A1 needs to be activated or transports through an
unidentified exchange transport mechanism or only transports a still unidentified,
specific substrate; though OATP5A1 seems to be widely expressed in many tissues.
OATP2B1 and OATP2A1 were identified in X. laevis oocytes and could influence the
uptake of potential OATP substrates [83]. Several lines of evidence suggest a crucial
role of the large extracellular loop region five, located between helix nine and helix
ten, in the transport activity of OATPs [113, 150]. A novel homology between this
region and the Kazal-1/2-type serine protease inhibitors has been detected, which
could be important for substrate binding [83, 143]. A typical Kazal domain contains
six cysteine residues leading to three disulfide bonds with a 1-5/2-4/3-6 pattern [68].
Ten cysteine residues for OATP5A1 were predicted in the extracellular loop region
five by the program TeXtopo (fig. 1.5). For the first time this Kazal-domain was
described in an integral membrane protein, but the precise function of this domain
in OATPs is still unknown [83].
The serine protease inhibitor families play a critical role in the precise regulation of
several serine proteases and affect many physiological events, such as blood coagu-
lation, development, food digestion, inflammation, and immune response [83]. Such
domains have also been found in a number of proteins that lack any known pro-
teinase inhibitor function including agrin, which is a proteoglycan that is involved
in the development of the neuromuscular junction (NMJ). Other Kazal-domain-
containing proteins are follistatin, which is an inhibitor of several TGF-β family
members, SPARC (osteonectin), which is required for the collagen in bone to be-
come calcified but is also involved in extracellular matrix synthesis and promotion
of changes to cell shape, CPAMD8 (complement 3 and pregnancy zone protein-like,
α2-macroglobulin domain-containing 8), a novel member of the complement 3/α2-
macroglobulin (C3/α2M) family which binds to heparin via its C-terminus where the
Kazal-domain is located [75], and complement component C6. Metabolic pathways
involving proteins with a Kazal-domain include the complement and coagulation cas-
cades, the ECM-receptor interaction pathway and the TGF-beta signaling pathway
[74, 136].
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3.4.2 Proliferation assay
Proliferation assays performed in Hela cells revealed an inhibitory effect on cell pro-
liferation after inducible expression of WT and mutant hSLOC5A1 compared to
mock cells. Genes identified by gene expression profiling might help to explain this
inhibitory effect. The WAP four-disulfide core domain 1 (WFDC1) was originally
identified as a secreted growth inhibitor with a serine protease inhibitor function.
It negatively regulates cell growth and epithelial cell proliferation. In contrast to
WFDC1, EPCAM (epithelial cell adhesion molecule) and HAS2 (hyaluronan syn-
thase 2) positively regulate epithelial cell proliferation but were found to be down-
regulated after hSLCO5A1 expression.
Transcriptional hSLCO5A1 expression in primary blood cells suggest that OATP5A1
might be involved in cell differentiation processes. Growth and proliferation are often
poorly compatible with differentiation.
3.4.3 Global gene expression
Gene expression profiling of hSLOC5A1 expression in Hela cells using exon expres-
sion arrays identified genes that are mainly involved in biological processes of cell
adhesion and system- and anatomical structure development, but also in the immune
response, the regulation of smooth muscle cell proliferation, synapse assembly and
organization, and cell proliferation.
DCs flexibly adapt to different microenvironments by using diverse migration strate-
gies that are ultimately dependent on the dynamics and structural organization of
the actin cytoskeleton. Genes involved in this process could be identified by mi-
croarray analysis of Hela cells expressing SLCO5A1. The signaling adaptor Eps8 is
an essential actin capping protein for dendritic cell migration [33]. The chemokine
CCL20 is a key factor for the recruitment of DCs into epithelial tissues. The cy-
tokine oncostatin M (OSM) induces dendritic cell maturation [54]. The gene OSMR
encodes a member of the type I cytokine receptor family which is necessary for the
response to OSM. The OSMR is involved in the postive regulation of acute inflam-
matory responses and the positive regulation of cell proliferation. OSM was also
found to regulate drug transporter expression in human hepatocytes [71]. All three
genes were found to be upregulated after SLCO5A1 expression in Hela cells, whereas
HAS2, which is responsible for hyaluronan synthesis, was found to be downregulated.
However, the differentiation of THP-1 monocytic cells to macrophages was associ-
ated with a > 800-fold increase in mRNA of HAS2 [23].
Recently, it has been shown that export transporters such as ATP binding cas-
sette (ABC) transporters and multidrug-resistance-associated proteins (MRPs) are
involved in human dendritic cell migration. MRP4 (ABCC4) inhibition in DCs
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resulted in reduced migration of DCs from human skin explants and of in vitro
generated Langerhans cells [153]. The Leukotriene C4 transporter MRP1 regulates
CCL19-dependent mobilization of dendritic cells out of the epidermis to lymph nodes,
as revealed by MRP1-/- mice studies [120]. In addition, MRP1 expressed in moDCs
transports contact allergens [141]. Often contact allergens require metabolic con-
version to become the nominative antigen. CYP1B1 represents a metabolic enzyme
expressed in DCs [139] and was also identified as gene upregulated after SLCO5A1
expression in Hela cells. CYP1B1 is involved in drug metabolism and synthesis of
cholesterol, steroids and other lipids but also in endothelial cell migration, endothe-
lial cell-cell adhesion and angiogenesis [2]. Data suggest that SLCO5A1 expression
and SLCO5A1-dependent gene regulation influence differentiation and migration pro-
cesses.
Furthermore, calcium-dependent cell adhesion molecules and calcium-dependent mole-
cules that are involved in system- and anatomical structure development were identi-
fied by microarray analysis, such as DSC3 (desmocollin 3), a member of the cadherin
superfamily, which is involved in cell adhesion and desmosome formation/protein sta-
bilization [10], and TGM2 (transglutaminase 2), which is induced by retinoic acid,
catalyzes the crosslinking of proteins by epsilon-gamma glutamyl lysine isopeptide
bonds, and is involved also in inflammatory responses [156]. Calcium acts as a second
messenger that initiates signaling cascades, leading to essential biological processes
such as secretion, cell proliferation, differentiation, and movement. It also regulates
the DC immune response including DC activation, maturation, migration, and for-
mation of immunological synapses with T cells. The immunological synapse exhibits
many similarities with classical neuronal synapses, including requirement for cell-to-
cell adhesion and close membrane apposition. Remarkably, not only cytokines but
also the neurotransmitter glutamate is released into the synaptic cleft between DCs
and T cells via calcium-dependent processes [138].
Pyramidal glutamatergic neurons that make up ∼75% of all neurons in the adult
cortex are projection neurons that send axons to other areas of the cortex and
to distant parts of the brain [155]. DPYSL3 (dihydropyrimidinase-like 3) shall
be involved in axon guidance and regulation of neuron projection development [2].
SEMA3A (semaphorin 3A) might be vital for normal neuronal pattern development
and can inhibit axonal outgrowth or stimulate the growth of apical dendrites [164].
SLC1A3 (solute carrier 1A3) represents a glial high affinity glutamate transporter.
EPHA7 (ephrin type-A receptor 7) has been implicated in mediating developmental
events, particularly in the nervous system. NEFH (neurofilament, heavy polypep-
tide) may play a role in intracellular transport to axons and dendrites [2]. MAP1B
(microtubule-associated protein 1B) was reported to be involved in microtubule-
assembly during neurogenesis [80]. PTPRF (protein tyrosine phosphatase, receptor
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type F) is involved in the process of dendritic spine formation [46].
Many genes identified in microarray analysis are also correlated with metastasis
based on changes of cell shape which can promote tumor cell invasion. This might
explain why OATP5A1 was found in so many cancerous tissues. The insulin-like
growth factor binding protein 5 (IGFBP5) is expressed in osteosarcoma and at lower
levels in the liver, kidney and brain. IGFBPs have been shown to either inhibit
or stimulate the growth promoting effects of the IGFs on cell culture. IGFBP5 is
involved in processes including hair follicle morphogenesis, mammary gland invo-
lution, negative regulation of smooth muscle cell migration and proliferation, and
osteoblast differentiation [2, 48]. The family members IGFBP1 and IGFBP7 contain
a Kazal domain, and IGFBP7 expression shall be a critical step in the development
of a BRAF V600E-positive melanoma [64]. H-cadherin (CDH13) is implicated in
the processes of keratinocyte proliferation, endothelial cell migration, and regula-
tion of epidermal growth factor receptor signaling pathway [91, 92]. The gene is
hypermethylated in many types of cancer. But CDH13 expression was shown to
reduce invasion of malignant melanoma [65]. WFDC1 (WAP four-disulfide core do-
main 1) is mapped to chromosome 16q24, an area of frequent loss of heterozygosity
in cancers, including prostate, breast and hepatocellular cancers. WFDC1 is one of
the most frequently down-regulated genes observed in human melanoma samples [78].
The human SLCO5A1 gene promoter contains binding sites for multiple transcription
factors such as MEF2A, POU3F2, Arnt, YY1, Pax-6, AP-1 and Sox9 (as predicted
by SABiosciences Mining Application and the UCSC Genome Browser [41, 56]). This
also suggests that SLCO5A1 might be involved in several cellular processes including
development, differentiation and cell growth control.
3.5 Conclusions
Results of the first part of this thesis showed that the sensitization potential of an-
tibiotics acting as haptens can be measured in vitro using THP-1 cells and moDCs
by detecting selected gene expression changes of inflammatory reactions, oxidative
and metabolic stress reactions and of transcriptional regulation processes implicated
in the sensitization phase of a drug-induced DTH reaction with the moDC cells being
the most sensitive ones. Thereby, most of the marker genes are suitable for detecting
the sensitization of beta-lactam antibiotics both in THP-1 and moDCs, however, in
a cell specific manner. In this respect, in vitro DC based assays might play a role in
the evaluation of the allergenic potential of novel drug compounds, but these systems
seem to lack the ability to detect the sensitizing potential of prohaptens that require
metabolic activation prior to sensitization.
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Nevertheless, these in vitro methods have certain limitations that have to be over-
come [124]. One limitation is that primary cells like moDCs exhibit donor-to-donor
variation in responsiveness. Protein reactivity, which is preliminary for sensitization,
thus, for gene expression changes, requires metabolic activation of chemicals unless
they are not naturally protein-reactive. Many drugs are organic in nature and in-
soluble in an aqueous matrix which complicates the delivery of the test compound.
Another major issue is related to the cell viability because cell systems have to be
treated with test drugs at the maximum non-toxic concentration in order to elicit
sensitization. This raises the question whether there is a need for some low-level cell
trauma or other ‘danger signals’ [79]. Probably, additional cell types could provide
this ‘signals’ which would implicate co-culture models. On the other hand, such
models also would complicate the development of a routine testing method.
However, in vitro DC based assays could represent a promising screening tool in
further investigations and could help to improve our understanding of the molecular
mechanisms involved in drug-induced DTH reactions.
Only very little is known about the organic anion transporting polypeptide OATP5A1.
Results of the second part of this thesis experimentally showed for the first time that
human OATP5A1 is expressed as a N-glycosylated polypeptide monomer that is lo-
calized in the cytosol/ in intracellular membranes and on the plasma membrane of
mammalian Hela cells and X. laevis oocytes. Furthermore, transcriptional analysis
of SLCO5A1 and functional studies provided evidence that OATP5A1 might be a
non-classical OATP family member, which is involved in biological processes that re-
quire the reorganization of the cell shape, such as differentiation and migration. This
finding would explain the increased expression of SLCO5A1/OATP5A1 in so many
cancerous tissues and cells throughout the body. But the substrate for OATP5A1
transport is still unidentified. Thus, further studies are required regarding the identi-
fication of substrates for OATP5A1. To resolve the question in which way OATP5A1
might be involved in differentiation and migration, thus in carcinogenesis and im-
mune reactions, more efforts are needed regarding the study of OATP5A1 function.
A systematic investigation of immune mechanisms that cause drug allergies and of
transporter polypeptides, such as the OATP family members, might help to reduce
adverse drug reactions.
4. Materials and Methods
Materials and Methods are described according to standard protocols used in the
Department of Dermatology, Institute of Pharmacology and Toxicology, and Institute
of Biochemistry of the Medical Faculty RWTH Aachen University. Protocols were
modified according to individual differences in experimental procedures.
4.1 Molecular Biology
4.1.1 Bacterial strains/ Materials
E. coli DH5α
(Invitrogen)
F-80dlacZ M15 (lacZYFA-argF) U169 recA1 endA1 hsdR17 (rk-mk+)phoA supE44
- thi-1 gyrA96 relA1
E. coli XL1-Blue
(Stratagene)
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´proAB lacI qZ4M15 Tn10
(Tetr)]
LB-medium (Roth): 10 g/l Tryptone
5 g/l Yeast Extract
5 g/l NaCl
pH 7,0
SOC-medium: LB-medium (Roth)
5,2mM KCl (Merck)
40mM MgCl2 (Merck)
20mM glucose (Merck)
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Agar-plates: LB medium (Roth)
1,5% (w/v) Bacto-Agar (AppliChem)
Antibiotics: 100 µg/ml Ampicillin or 50 µg/ml Kanamycin
4.1.2 Plasmids
pDONRTM221
pDONRTM221 vector (cat. no. 12536-017, Invitrogen/ Life Technologies) is a Gatewayr-
adapted vector designed to generate attL-flanked entry clones containing the gene
of interest following recombination with an attB expression clone or an attB PCR
product (fig. 4.1).
pNKS4_GW
The oocyte expression vector pNKS4 originates from pNKS2 [37]. pNKS2 was mod-
ified by optimizing the 5´-untranslated region and by insertion of a NotI and two
XhoI restriction sites after the polyA-tail in the 3´-untranslated region for lineariza-
tion.
pNKS4 contains a Gateway cassette (GW) for Gatewayr recombinational cloning
(Invitrogen/ Life Technologies). The destination vector pNKS4_GW was created by
ligating a blunt-ended reading frame cassette A (RfA) containing attR sites flanking
the ccdB gene and the chloramphenicol resistance gene into the multiple cloning site
of pNKS4 (fig. 4.2).
pOG44
pOG44 (cat. no. V6005-20, Invitrogen/ Life Technologies) is a 5,8 kb Flp recombi-
nase expression vector designed for use with the Flp-InTM T-RExTM System available
from Invitrogen (Life Technologies). The pOG44 plasmid constitutively expresses the
Flp recombinase [20, 19, 22] under the control of the human CMV promoter (fig. 4.3).
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Figure 4.1: Map and features of pDONRTM221.
pcDNATM5/FRT/TO_GW
pcDNATM5/FRT/TO (cat. no. V6520-20) is a 5,1 kb inducible expression vec-
tor designed for use with the Flp-InTM T-RExTM System available from Invitro-
gen (Life Technologies). The pcDNA5/FRT/TO© plasmid contains the gene of
interest under the control of a tetracycline-regulated, hybrid human cytomegalovirus
(CMV)/TetO2 promoter. The vector also contains the hygromycin resistance gene
with a FRT site embedded in the 5´ coding region. To create the destination vec-
tor pcDNA5/FRT/TO_GW the Gateway cassette (GW) reading frame cassette A
(RfA) was introduced for Gatewayr recombinational cloning (fig. 4.4).
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Figure 4.2: Map of pNKS4 with RfA cassette (Invitrogen) for Gatewayr recombinational
cloning
Figure 4.3: Map and features of pOG44.
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Figure 4.4: Map of pcDNATM5/FRT/TO_GW.
pEYFP-N1
pEYFP-N1 (#6006-1, Clontech/Takara Bio Europe, Saint-Germain-en-Laye, France)
was a gift from the Institute of Biochemistry of the Medical Faculty, RWTH Aachen.
pEYFP-N1 encodes an enhanced yellow-green variant of the Aequorea victoria green
fluorescent protein (GFP). The MCS in pEYFP-N1 is between the immediate early
promoter of CMV (PCMVIE) and the EYFP coding sequences. The vector contains an
SV40 origin of replication and a neomycin resistance (Neor) gene for selection (using
G418) in mammalian cells. A bacterial promoter upstream of this cassette (P) ex-
presses kanamycin resistance in E. coli. The vector backbone also provides a pUC19
origin of replication for propagation in E. coli and an f1 origin for single-stranded
DNA production (fig. 4.5).
66 Materials and Methods
Figure 4.5: Restriction Map and Multiple Cloning Site (MCS) of pEYFP-N1. Unique
restriction sites are in bold.
4.1.3 Oligonucleotides
The following nucleotides were purchased from Eurofins MWG Operon, Applied
Biosystems or Eurogentec (see table 4.1, table 4.2, and table 4.3).
Table 4.1: PCR primers
PCR primers
Primer name Sequence (5´-3´) Function
hSLCO5A1_fw GGGGACAAGTTTGTACAAAA
AAGCAGGCTGCCATGGACGA
AGGCACT
amplification of full-
length hSLCO5A1 from
cDNA of mature dendritic
cells, insertion of attB
recombinational cloning
sites
hSLCO5A1_rev GGGGACCACTTTGTACAAGA
AAGCTGGGTTCAGGAGGGCG
GCTCCAA
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Primer name Sequence (5´-3´) Function
hSLCO5A1_
F33L_fw
GCGAGCCGGAGACCCTCAGGT
CTAAGAGTTTACCGG
modification of SNP
L33F to wild-type se-
quence, insertion of a
Bsu36I restriction site
hSLCO5A1_
F33L_rev
CCGGTAAACTCTTAGACCTGA
GGGTCTCCGGCTCGC
His-
hSLCO5A1_fw
CCAGTGCCTTCGTCGTGATGG
TGATGGTGATGCATGGCAGCC
TGCTTTTTTG
introduction of a hexahis-
tidyl (His) tag 3´ or 5´ of
the ATG start codon, in-
sertion of a NsiI restric-
tion site
His-
hSLCO5A1_rv
CAAAAAAGCAGGCTGCCATG
CATCACCATCACCATCACGAC
GAAGGCACTGG
hSLCO5A1-
His_fw
CAAGAAAGCTGGGTTCAGTG
GTGGTGGTGGTGGTGAGACG
GCGGCTCCAAGG
introduction of a hexahis-
tidyl tag 3´ or 5´ of the
stop codon, insertion of a
BsmAI restriction site
hSLCO5A1-
His_rv
CCTTGGAGCCGCCGTCTCAT
CACCATCACCATCACTGAAC
CCAGCTTTCTTG
hSLCO5A1-
HA_fw
GGAGCCGCCCTCCTACCCAT
ACGATGTTCCAGATTACGCT
TGAGCTCAGCTTTCTTGTAC
AAAG
introduction of a C-
terminal haemagglutinin
(HA) tag, insertion of a
SacI restriction site
hSLCO5A1-
HA_rv
CTTTGTACAAGAAAGCTGAG
CTCAAGCGTAATCTGGAACA
TCGTATGGGTAGGAGGGCGG
CTCC
hSLCO5A1-
LiNhe_fw
GGAGCCGCCCTCCGGCGGCG
AGCAGAAGCTGGCTAGCCCC
AGCTTTCTTGTAC
C-terminal modification
of the stop codon, inser-
tion of a linker sequence,
and insertion of a NheI
restriction site
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Primer name Sequence (5´-3´) Function
hSLCO5A1-
LiNhe_rv
GTACAAGAAAGCTGGGGCTA
GCCAGCTTCTGCTCGCCGCC
GGAGGGCGGCTCC
hSLCO5A1-YFP-
Frame_fw
CAGAAGCTGGCTAGCGTACC
GGACTCAGATCTC
correction of frameshift
of hSLCO5A1-YFP se-
quence, deletion of an
AfeI restriction site
hSLCO5A1-YFP-
Frame_rv
GAGATCTGAGTCCGGTACGCT
AGCCAGCTTCTG
Table 4.2: Sequencing primers
Sequencing primers
Primer name Sequence (5´-3´) Function
6020 CTTACCTCACTTCATCTCGC Sequencing pNKS4-hSLCO5A1
6023 CTGTTGATGCTGTTAGTGATGAC Sequencing hSLCO5A1
(bp 1283-1305)
7273 CCTACTCAGACAATGCGATG Sequencing hSLCO5A1
(bp 3614-3633)
7274 CCGTAGAAGATGAGGAGAGAC Sequencing hSLCO5A1
(bp 2111-2131)
4.1.4 Preparation of plasmid DNA
Bacterial cultures
Single cell colonies were selected for plasmid DNA preparation. For small-scale
preparations 3ml LB medium and for large-scale preparations 100ml (Midi) or 300ml
(Maxi) LB medium supplemented with the respective antibiotic was incubated at
37°C under continous shaking at 220 rpm.
Preparation of plasmid DNA
For large scale preparations plasmid DNA was extracted using the Nucleobond Xtra
Midi/Xtra Maxi plus kit (Macherey-Nagel, Düren, Germany) and for small-scale
preparations plasmid DNA was extracted using the Fast Plasmid Mini kit (5 Prime,
Hamburg, Germany) according to the manufacturer’s recommendations.
4.1.5 Enzymatic modification of plasmid DNA
Plasmid DNA was modified and digested with restriction enzymes purchased from
NEB (Frankfurt/Main, Germany) or Fermentas (St. Leon-Rot, Germany). Restric-
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Table 4.3: Primer for qRT-PCR
TaqManr primer/probe sets
for qRT-PCR (Applied Biosystems)
Target TaqManr gene expression
assay number
GAPDH Hs99999905_m1
HPRT Hs99999909_m1
18S Hs99999901_s1
GUSB Hs99999908_m1
SLCO5A1 Hs00229597_m1
CES1 Hs00275607_m1
NQO1 Hs00168547_m1
PIR Hs00186374_m1
TRIM16 Hs00414879_m1
IL-8 Hs00174103_m1
IL-1beta Hs00174097_m1
GCLM Hs00157694_m1
OSMR Hs00384276_m1
DSC3 Hs00170032_m1
TGM2 Hs00190278_m1
CCL20 Hs01011368_m1
CYP1B1 Hs00164383_m1
tion enzymes mainly used included Bsu36I, NsiI, BsmAI, SacI, NheI, NotI and AfeI.
Plasmid DNA digestions were performed in 20-50 µl volume for ∼2h including the
appropriate buffers at the respective temperatures according to the manufacturer’s
recommendations. Plasmid DNA was ligated with T4 DNA Ligase purchased from
NEB and T4 ligase buffer in a reaction volume of 20 µl for ∼5h at RT.
4.1.6 Agarose gel electrophoresis and DNA extraction
Gel electrophoresis was performed with 0,8 - 1% agarose (peqGOLD universal agarose,
peqLab, Erlangen, Germany) as described by Sambrook et al. [126].
DNA was isolated from an agarose gel and purified using the QiaQuick Gel Extraction
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s recommendations.
4.1.7 Polymerase chain reaction (PCR) for amplification of DNA
For a 50 µl reaction volume:
25 µl Phusion High Fidelity PCR Master Mix
(Finnzymes, Vantaa, Finland)
2,5 µl Oligo 1 (5 µM)
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2,5 µl Oligo 2 (5 µM)
5 µl cDNA (250 ng)
5 µl 10% DMSO
10 µl water
PCR program (Thermo Light Cycler, Eppendorf):
Initial denaturation 95°C 30 sec
30 cycles:
Denaturation 95°C 30 sec
Annealing 57°C 45 sec
Elongation 72°C 2min 30 sec
Final extension 72°C 10min
4.1.8 PCR mutagenesis with modified primers
In vitro site-directed mutagenesis was performed with the QuikChangeTM Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA, USA) using mutagenic primers. The kit
is used to make point mutations, switch amino acids, and delete or insert multiple
amino acids.
For a 50 µl reaction volume:
25 µl Phusion High Fidelity PCR Master Mix
(Finnzymes, Vantaa, Finland)
125 ng Primer
5-50 ng DNA
8% DMSO
up to 50 µl water
PCR program:
Initial denaturation 98°C 1min
12 cycles for point mutations/
18 to 22 cycles for multiple amino acid insertions:
Denaturation 95°C 30 sec
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Annealing 55°C 1min
Elongation 68°C 10-17min
(2 min/kb of
plasmid length)
1 µl DpnI was added to the PCR product and incubated for 1,5h at 37°C. DpnI
endonuclease is specific for methylated and hemimethylated DNA and is used to
digest the parental DNA template and to select for mutation-containing synthesized
DNA [99].
4.1.9 Bacterial Transformation
For Site Directed Mutagenesis 5 µl DpnI-PCR product was added to 50 µl zymocom-
petent XL1-Blue (Stratagene) cells and incubated for 10min on ice. Then, 400 µl
SOC-medium was added. The mix was incubated for 45min at 37°C in a shaker at
220 rpm. Cells were plated on LB agar plates containing the appropriate antibiotic
for selection. After Gatewayr cloning or for Re-Transformation DNA was added to
50 µl or to 100 µl zymocompetent DH5α (Invitrogen) cells. Cells were incubated on
ice for 10min. E. coli transformed with plasmids containing an ampicillin-resistance
were directly plated on LB-ampicillin agar plates. To cells, transformed with plas-
mids containing a kanamycin-resistance, 400 µl SOC-medium was added and bacteria
were incubated at 37°C for 1h in a shaker at 220 rpm. Then, cells were plated on LB
agar plates containing the appropriate antibiotic for selection.
Zymocompetent cells were generated using the Z-Competent E. coli Transformation
Kit from ZYMO RESEARCH (Freiburg, Germany) according to the manufacturer’s
recommendations.
4.1.10 Cloning of DNA fragments
All plasmids were created using the Gatewayr cloning system (Invitrogen, Darm-
stadt, Germany) [58]. The Gatewayr Technology is a universal cloning method that
takes advantage of the site-specific recombination properties of bacteriophage lambda
[67] to provide a rapid and highly efficient way to move the gene of interest into mul-
tiple vector systems (fig. 4.6).
ORF (open reading frame) sequence for human SLCO5A1 (transcript variant 1;
NCBI Reference Sequence: NM_030958.2) was amplified by PCR using cDNA iso-
lated from mature dendritic cells with a primer pair containing recombinational
cloning sites (attB) for Gatewayr recombinational cloning. The PCR product of
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2602 bp was isolated from an agarose gel using the QiaQuick Gel Extraction Kit ac-
cording to the manufacturer’s instruction (Qiagen, Hilden, Germany). The hSLCO-
5A1-Entry clone was created with the attB-PCR product and the donor vector
pDONRTM221 using the Gatewayr BP ClonaseTM II enzyme mix according to the
manufacturer’s instruction (Invitrogen, Darmstadt, Germany).
Figure 4.6: Gatewayr recombinational cloning
FlpIn T-Rex-Hela cells
The hSLCO5A1 coding sequence was subcloned into the mammalian inducible ex-
pression vector pcDNA5/FRT/TO_GW using the Gatewayr LR ClonaseTM II en-
zyme mix according to the manufacturer’s instruction (Invitrogen, Darmstadt, Ger-
many). DNA sequences were confirmed by sequencing and revealed a single nu-
cleotide polymorphism (SNP) on position 33 (L→F). According to UniprotKB (ref.
seq. Q9H2Y9) this sequence corresponds to a natural variation. This SNP was
modified to the wild-type (WT) sequence with mutagenic primers that incorporated
a Bsu36I restriction site. The plasmids pcDNA5/FRT/TO-hSLCO5A1WT/L33F were
either C-terminally HA (Haemagglutinin)-tagged (5´-YPYDVPDYA-3´) using mu-
tagenic primers that incorporated a silent SacI restriction site or were YFP-tagged.
The YFP-Tag was attached in two cloning-steps. In a first step mutagenic primers
were used which modified the stop codon, inserted a linker sequence and inserted
a NheI restriction site C-terminally of the hSCLO5A1WT/L33F sequence. In a sec-
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ond step, the modified plasmids and the vector pEYFP-N1 (for obtaining the YFP
sequence) were digested with the restriction enzymes NheI and NotI (NEB, Frank-
furt/Main, Germany) isolated from an agarose gel using the QiaQuick Gel Extraction
Kit according to the manufacturer’s instruction (Qiagen, Hilden, Germany) and lig-
ated with a T4 DNA-Ligase-Kit (NEB, Frankfurt/Main, Germany) (fig. 4.7).
Figure 4.7: Schematic presentation of expression constructs pcDNA5/FRT/TO-
hSLCO5A1WT/L33F/-HA/-YFP
Xenopus laevis oocytes
The hSLCO5A1 coding sequence was subcloned into the oocyte expression vector
pNKS4_GW [37] using the Gatewayr LR ClonaseTM II enzyme mix according to
the manufacturer’s instruction (Invitrogen, Darmstadt, Germany). DNA sequences
were confirmed by sequencing and revealed a single nucleotide polymorphism (SNP)
on position 33 (L→F). According to UniprotKB (ref. seq. Q9H2Y9) this sequence
corresponds to a natural variation. Again, this SNP was modified to the wild-
type (WT) sequence with mutagenic primers that incorporated a Bsu36I restriction
site. Additionally, a hexahistidyl (His) tag was introduced immediately 3´ or 5´
of the ATG start codon or the stop codon, respectively, to generate pNKS4-His-
hSLCO5A1WT/L33F and pNKS4-hSLCO5A1WT/L33F-His by using mutagenic primers
that incorporated a silent NsiI or BsmAI restriction site (fig. 4.8).
4.1.11 DNA analysis/ Sequencing
During all cloning steps positive clones were identified using restriction-enzyme anal-
ysis. DNA sequences were confirmed by sequencing using specific primers. Sequenc-
ing was performed by Eurofins MWG Operon.
74 Materials and Methods
Figure 4.8: Schematic presentation of expression constructs pNKS4-hSLCO5A1WT/L33F/-
N-His /-C-His
4.1.12 Linearization and purification of DNA for cRNA - synthesis
Linearization of DNA was performed with the restriction enzyme XhoI using a reac-
tion volume of 70 µl. XhoI cleaved the DNA once 3´ after the PolyA tail. Purification
of DNA was performed with the Qiaquick Nucleotide Removal Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s recommendations. 22,2 µl sodium ac-
etate, pH 5,2 (3M) (Sigma) and 444 µl ethanol (100%) (Merck) were added to 200 µl
eluted DNA and precipitated at -20°C.
4.1.13 In vitro transcription - cRNA synthesis
Transcription buffer: 15mM MgCl2
2mM Spermidine
80mM Hepes-KOH, pH 7,5
40mM DTT
Inorganic Pyrophosphatase (5U/ml)
Precipitated DNA was centrifuged (13200 rpm, 4°C), washed with 70% ethanol, dried
at RT, and dissolved in 31 µl 0,5x TE buffer. 0,5-1 µg DNA was transcribed in vitro
with SP6 polymerase (Epicentre Biotechnologies, Madison, USA), rNTPs (rNTP set,
GE Healthcare, Freiburg, Germany), and cap-nucleotides (RNA ARCACap Analo-
gon, Jena Bioscience, Jena, Germany) in transcription buffer at 37°C. cRNA was
purified by sepharose gel chromatography (AutoSeqTM G-50 columns, GE Healthcare,
Freiburg, Germany) to remove free nucleotides. Remaining proteins were removed by
phenol-chloroform-extraction. Then, cRNA was precipitated, washed and dissolved
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in 5mM Tris/HCl, pH 7,4 (Sigma). Concentration was determined by photometric
measurement (260 nm) (BioPhotometer, Eppendorf). Integrity of cRNA was con-
firmed by gel electrophoresis. cRNA was frozen at -80°C.
cRNA synthesis was performed by Silvia Detro-Dassen (Institute of Pharmacology
and Toxicology, Medical Faculty, RWTH Aachen University).
4.1.14 RNA isolation
Cells were lysed and homogenized using QIAshredder spin columns (Qiagen, Hilden,
Germany). Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions, including on column digestion
of DNA with RNase-free DNase I. RNA was quantified by photometric measurement
(Nanodrop Technologies, Wilmington, Delaware, USA). The obtained amounts of
RNA were used for cDNA synthesis. For exon expression arrays, RNA integrity has
been proven by using the 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA,
USA).
4.1.15 Reverse transcription PCR - cDNA synthesis
1 µg of total RNA per 100 µl reaction was reverse transcribed using the High Capac-
ity RNA-to-cDNA Master Mix (Applied Biosystems, Darmstadt, Germany) or the
SuperScriptr VILOTM MasterMix (Invitrogen, Darmstadt, Germany) according to
the manufacturer’s instruction.
4.1.16 Analysis of transcription by quantitative real-time reverse transcrip-
tase polymerase chain reaction (qRT-PCR)
TaqMan experiments were carried out on an ABI PRISM 7300 Sequence Detection
System (Applied Biosystems, Darmstadt, Germany) using TaqMan gene expression
assay products according to the manufacturer’s recommendations. A PCR Reaction
Mix (20 µl) was prepared by using the following reaction components: TaqMan Gene
Expression Master Mix (1x), 40 ng of cDNA and water. Human Primer/probe sets
were obtained from the Applied Biosystems Assays-On-Demand repository (table
4.3). Assay-on-Demand products for GAPDH, 18S and GUSB were used as an
internal reference to normalize the target transcripts. Results were analyzed with
the 7300 System SDS Software (Applied Biosystems, Darmstadt, Germany).
4.1.17 Analysis of gene expression using the Affymetrix GeneChip Human
Exon 1.0 ST array
RNA samples of mock T-Rex-Hela cells (pcDNA5-FRT/TO) respectively wild-type
hSLCO5A1-expressing T-Rex-Hela cells both treated with 1 µg/ml tetracycline were
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collected. The Ambionr WT Expression Kit (Ambion, Kaufungen, Germany) was
used to generate purified sense-strand cDNA with incorporated dUTP according to
the technical manual. Fragmentation and labeling was done using the Affymetrix
Gene Chipr WT Terminal Labeling kit (Affymetrix, Santa Clara, CA, USA) ac-
cording to the manufacturer’s recommendations [109]. Each sample was hybridized
to a Gene Chip Human Exon 1.0 ST array for 16h at 45°C. Expression values of
each probe were determined and the mock sample was compared to the wild-type
hSLCO5A1 sample using the GeneSpringr GX 12.0 software (Agilent Technologies,
Frankfurt/Main, Germany). Genes with a fold change of larger than 2.0 were ana-
lyzed.
4.1.18 Expression systems
Heterologous expression in mammalian cells
FlpIn T-REx-Hela cells The Flp-InTM T-RExTM System allows the generation of
stable mammalian cell lines exhibiting tetracycline-inducible expression of a gene of
interest from a specific genomic location. FlpIn T-Rex-Hela cells (cervix carcinoma
cells), stably expressing the lacZ-Zeocin fusion gene and the Tet repressor and con-
taining a single FRT site, were provided from Prof. Müller-Newen (Department of
Biochemistry, University Hospital Aachen) (fig. 4.9) (for more information see the
Flp-In T-Rex Core Kit Manual cat. no. K6500-01 from Invitrogen, Darmstadt,
Germany).
Figure 4.9: FlpInTM T-RExTM-Hela cell line. The cell line contains two stably, inde-
pendently integrated plasmids. The pFRT/lacZeo plasmid introduces a single FRT (Flp
recombination target) site into the genome and stably expresses the lacZ-ZeocinTM fusion
gene under the control of the SV40 early promoter. The pcDNA6/TR plasmid stably ex-
presses the Tet repressor gene under the control of the constitutive human cytomegalovirus
(CMV) immediate-early enhancer/ promoter [9, 18, 98].
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Stable transfection Stably transfected FlpIn T-Rex-Hela cells were generated us-
ing the FlpIn recombinase-mediated system kit (Invitrogen, Darmstadt, Germany),
which permits the targeted integration of genes to the same locus in all transfected
cells to provide a homogeneous level of gene expression. To this effect, cells were co-
transfected with the Flp-In expression vectors pcDNA5/FRT/TO-hSLCO5A1WT/L33F/-
HA /-YFP or as control with the vector pcDNA5/FRT/TO_GW (mock) together
with the Flp-recombinase expression vector pOG44 (Invitrogen, Darmstadt, Ger-
many) in a ratio of 1:9 using the transfection reagent TransITr-LT1 (Mirus, Madi-
son, WI, USA) according to the manufacturer’s instructions. The Flp recombinase
expressed from pOG44 catalyzes a homologous recombination event between the FRT
sites in the host cells and the pcDNA5/FRT/TO_GW expression vector. Integra-
tion of the expression construct confers hygromycin resistance to the cells. Individual
clones were separated by monoclonal selection with 15 µg/ml blasticidin (Invitrogen,
Darmstadt, Germany) and 100 µg/ml hygromycinB (PAA, Pasching, Austria).
Induction of gene expression - the inducible Tet-system The Flp-InTM T-RExTM Sys-
tem uses regulatory elements from the E. coli Tn10 -encoded tetracycline (Tet) re-
sistance operon [44, 45] to allow tetracycline-regulated expression of the gene of
interest from pcDNA5/FRT/TO. The mechanism of tetracycline regulation in the
system is based on the binding of tetracycline to the Tet repressor and derepression
of the promoter-controlling expression of the gene of interest [162] (fig. 4.10). Ex-
pression of hSLCO5A1 was induced by adding 1 µg/ml tetracycline (Sigma-Aldrich,
St. Gallen, Switzerland) to the cells.
Figure 4.10: Regulation of gene expression through the inducible Tet-system.
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Expression in Xenopus laevis oocytes/ Labeling of proteins
ORI: 90mM NaCl
1mM KCl
1mM CaCl2
1mM MgCl2
10mM HEPES
pH 7,4
oocyte-PBS: 20mM NaH2PO4
110mM NaCl
1mM MgCl2
pH 8,5 (with NaOH)
Collagenase-defolliculated Xenopus oocytes (stage V or VI) were injected with 50 nl
of capped cRNAs (0,03-1 µg/µl) or with Tris/HCl as control and kept at 17°C in
sterile ORI containing gentamycin (50mg/l). After injection, oocytes were metabol-
ically labeled by overnight incubation with L-[35S]-methionine (Amersham Buchler,
Braunschweig, Germany) (pulse). Oocytes were washed with Ca2+-free ORI in order
to avoid the activation of Ca2+-dependent proteases. After incubation of oocytes
in gentamycin-ORI for another day (chase), oocytes were surface-labeled with the
membrane-impermeable infrared (IR) dye 800-NHS just prior to protein extraction.
IR-800-NHS dye is covalently linked to lysine residues that are accessible on the ex-
ternal oocyte surface. Thereafter, 10 oocytes per group were washed 3 times with
oocyte-PBS and were transferred to reaction vessels coated with oocyte-homogenate.
Oocytes were incubated with 100 µl oocyte-PBS containing 0,5 µl IR-800-NHS dye
for 60min at RT in the dark. Again, oocytes were washed 3 times with oocyte-PBS.
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4.2 Cell Culture
Thankfully, the murine dendritic cells were provided by an employee of Prof. Zenke
(Institute of Cell Biology, Medical Faculty, RWTH Aachen University).
4.2.1 Media and Supplements, Buffers and Plastic Materials
All media were purchased from Gibco/Invitrogen, Darmstadt, Germany.
RPMI 1640 + GlutaMAXTM-I
RPMI 1640
Minimum Essential Medium alpha (MEM-α) + GlutaMAXTM-I
McCoy’s 5a
Eagle’s Minimum Essential Medium (EMEM)
Human heat-inactivated serum
Human heat-inactivated autologous plasma
FCS (heat-inactivated) (Biochrom, Berlin, Germany)
Non-essential amino acids (100x) (PAA, Pasching, Austria)
Sodium pyruvate solution (100mM) (PAA)
L-Glutamine (200mM) (PAA)
Tetracycline hydrochloride (5 g) (Sigma-Aldrich, St. Gallen, Switzerland)
Zeocin (1 g) (Invitrogen)
Blasticidin (50mg) (Invitrogen)
Hygromycin B solution (50mg/ml) (PAA)
Trypsin/EDTA (0,25/0,01% (w/v) in PBS) (Lonza, Verviers, Belgium)
β-mercaptoethanol (14,3 M) (Sigma-Aldrich/Fluka)
1x Phosphate buffered saline (PBS) (Gibco/Invitrogen)
Cell culture dishes, ∅ 6 cm/10 cm (Sarstedt, Nuembrecht, Germany)
Cell culture plates, 6-well/12-well/24-well/48-well/96-well (BD/Falcon, Heidelberg,
Germany)
Cell culture flasks, 25 cm2/75 cm2/175 cm2 (Greiner Bio One, Frickenhausen/Solingen,
Germany)
Cryovials (1ml) (Nalgene/Thermo Scientific, Rochester, NY, USA)
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4.2.2 Isolation and cultivation of human blood-derived primary monocytes
Human peripheral blood mononuclear cells (PBMCs) were separated from buffy coats
(Department of transfusion medicine, University Hospital Aachen, Germany) over
a Ficoll-Paque gradient (Amersham Pharmacia Biotech, Uppsala, Sweden). CD3,
CD7, CD16, CD19, CD56, CD123 and Glycophorin A positive leukocytes were de-
pleted using a negative monocyte isolation kit (Human Monocyte Isolation Kit II,
Miltenyi Biotec, Bergisch Gladbach, Germany). The isolated monocytes were cul-
tured in medium consisting of RPMI 1640 + GlutaMAXTM-I with 10% human serum.
Monocytes were harvested on day one and macrophages on day six to seven. For
the generation of DC, monocytes were cultured in 6-well plates at a density of 1x106
cells/ml in 3ml RPMI 1640 + GlutaMAXTM-I supplemented with 3% autologous
plasma in the presence of 800U/ml GM-CSF and 1000U/ml IL-4 (R&D-Systems,
Bühlmann, Basel, Switzerland) for six days. Replacement of 1ml cytokine contain-
ing medium every other day was done according to the protocol of Jonuleit et al.
[52]. On day six the immature dendritic cells were harvested. On day seven mat-
uration of DC was induced with medium containing a cocktail of pro-inflammatory
cytokines (IL-6, IL-1β, TNFα (R&D-Systems)) together with PGE2 (Sigma-Aldrich,
St. Gallen, Switzerland) as described by Jacobs et al. [49]. On day nine to ten cells
were harvested. Lysates were frozen at -80°C.
Cytokines
(see table 4.4)
Table 4.4: Cytokines
Recombinant human (rh) cytokines
term cat. no. company final concentration
rhIL-4 204-IL-050/CF R & D-Systems 500-1000 IU/ml
rhGM-CSF 215-GM-050/CF R & D-Systems 800-1600 IU/ml
rhTNFα 210-TA-050/CF R & D-Systems 10 ng/ml
rhIL-6 206-IL-050/CF R & D-Systems 1000 IU/ml
rhIL-1β 201-LB-025/CF R & D-Systems 10 ng/ml
PGE2 P0409 Sigma 1 µg/ml
4.2.3 Xenopus laevis oocytes
Oocytes were isolated from the south african clawed frog Xenopus laevis as described
by Schmalzing et al. [133].
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4.2.4 Cell lines
THP-1 cells
Human THP-1 monocytic-like cells were obtained from the German Collection of
Microorganisms and Cell Cultures (Braunschweig, Germany) and cultured as sus-
pension cells in RPMI-1640 supplemented with 10% FCS at 37°C in a 5% CO2
humidified incubator. The cells were sub-cultured at a split ratio of 1:4 to 1:6 and
passaged every 3-4 days. For stimulation with antibiotics THP-1 cells were plated
in 6-well-plates at a density of 3x106 cells per well.
MUTZ-Langerhans cells (LCs)
The CD34+ human acute myeloid leukemia cell line MUTZ-3 was purchased from the
German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany)
and cultured in Minimum Essential Medium alpha (MEM-α) + GlutaMAXTM-I with
ribonucleosides and deoxyribonucleosides supplemented with 20% FCS, 2mM L-
Glutamine, 50 µM β-Mercaptoethanol and 10% of conditioned medium from the
renal cell carcinoma cell line 5637 at 37°C in a 5% CO2 humidified incubator. Cells
were sub-cultured at a split ratio of 1:2 two times per week.
In order to generate immature MUTZ-LC (MUTZ-Langerhans cells) from MUTZ-3
progenitor cells, MUTZ-3 cells were cultured at a density of 1x105 cells/ml in 12-
well-plates for 9 days in complete medium without conditioned medium of 5637 cells
supplemented with 100 ng/ml GM-CSF, 10 ng/ml TGF-β and 2,5 ng/ml TNF-α. At
days 3 and 6 cytokines equivalent to 1ml of medium were added to each well. Cells
were stimulated with antibiotics at day 9.
Renal cell carcinoma 5637 cells
5637 cells were purchased from the German Collection of Microorganisms and Cell
Cultures (Braunschweig, Germany) and cultured in RPMI-1640 medium supple-
mented with 10% FCS and 50 µM β-Mercaptoethanol at 37°C in a 5% CO2 hu-
midified incubator. Cells were subcultured at a split ratio of 1:4 to 1:5 two times
per week. For the generation of conditioned medium cells were cultured in 175 cm2
tissue culture flasks with 5x105 cells/ml in 30ml of medium. After 24h new culture
medium was added. After 6 48h the conditioned culture medium was prepared by
removing the cell debris and by filter sterilising using a 0,2 µm filter. The conditioned
medium was stored at -20°C.
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Melanoma cell culture
Melanoma cell lines Mel-Ho, Mel-Juso and SK-MEL-30 were obtained from the Ger-
man Collection of Microorganisms and Cell Cultures (DSMZ) (Braunschweig, Ger-
many) and cultured in 90% RPMI1640 + 10% FCS. Melanoma cell lines G-361,
SK-MEL-5, SK-MEL-24, and SK-MEL-31 were obtained from the American Type
Culture Collection (ATCC) (Manassas, VA, USA). G-361 cells were cultured in Mc-
Coy’s 5a supplemented with 2mM L-glutamine and 10% FCS. SK-MEL-5 cells were
cultured in Eagle’s Minimum Essential Medium (EMEM) supplemented with 10%
FCS. SK-MEL-24 cells were cultured in EMEM supplemented with 1% non-essential
amino acids, 1mM sodium pyruvate and 15% FCS. SK-MEL-31 cells were cultured
in EMEM supplemented with 2mM L-glutamine, 0,1mM non-essential amino acids,
1mM sodium pyruvate and 15% FCS.
FlpIn T-Rex-Hela cells
Cells were cultured in MEM supplemented with Earles’s and L-glutamine and 1%
non-essential amino acids as well as heat-inactivated 10% FCS (tetracycline/doxy-
cycline-reduced) (Biochrom, Berlin, Germany). Expression was induced in the cells
by adding 1 µg/ml tetracycline for 24 to 48h.
4.2.5 Stimulation of antigen-presenting cells with antibiotics
THP-1 cells (3 experiments), MUTZ-LCs (3 experiments) and moDCs (6 exper-
iments) (on day 6) were incubated with the penicillins benzylpenicillin (PenG),
phenoxymethylpenicillin (PenV) and ampicillin (Amp) and the sulphonamide sul-
famethoxazole (SMX). The model irritant sodium dodecyl sulfate (SDS) and the
strong sensitizer 2,4,6-trinitrobenzene sulfonic acid (TNBS) served as negative and
positive control, respectively. The test compounds (purchased from Sigma Aldrich)
were individually prepared in complete medium (SDS 2,5µg/ml; TNBS 200µg/ml;
benzylpenicillin 7mg/ml; phenoxymethylpenicillin 2,5mg/ml; ampicillin 2,5mg/ml)
or solubilized in DMSO (sulfamethoxazole 1mg/ml). DMSO was also used as drug-
solution control (1%). Each test solution was incubated with at least 3x106 cells of
moDCs, MUTZ-LCs or THP-1 cells for 48h, respectively. Cells were harvested, lysed
and homogenized (QIAshredder, Qiagen, Hilden, Germany) and stored at -80°C prior
to further analysis.
4.2.6 Cryoconservation
For each cryovial 1-5x106 cells were pelleted and dissolved in 1ml of freezing medium
(90% FCS/10% DMSO or 70% cell culture medium/20% FCS/10% DMSO). The
cryovials were placed in an isopropanol chamber and stored at -80°C overnight. For
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long term storage the cryovials were transferred to a storage container filled with
liquid nitrogen.
4.2.7 Thawing of cells
Cryovials with frozen cells were thawed immediately in a water bath at 37°C. Cells
were transferred to Greiner Bio One tubes filled with 37°C warm cell culture medium.
Then, cells were pelleted by centrifugation and seeded in culture medium in the
appropriate culture dish.
4.2.8 Seeding and Passaging of cells
Suspension cells were subcultured by splitting cells in the appropriate amount to
new cell culture flasks containing fresh cell culture medium.
Adherent cells were washed once with 1x PBS to remove bivalent ions that would in-
activate trypsin and were detached from the culture dish surface with Trypsin/EDTA.
Trypsin was inactivated by addition of fresh medium to the detached cells. Cells in
their appropriate dilutions were seeded into new culture dishes.
4.2.9 Counting of cells
Cells were either counted after staining with trypan blue to distinguish between
viable and dead cells in a Neubauer counting chamber or by using the Casy Cell
Counter System (Innovatis/Roche, Mannheim, Germany).
4.2.10 Cell proliferation assay
Cells were seeded in 6-well plates in triplicates. After two hours at 37°C and 5%
CO2 cells were treated with 1 µg/ml tetracyclin or left untreated. For a period of
four days, every 24h cells were detached by adding 300 µl Trypsin/EDTA. Trypsin
was inactivated by adding 1ml of culture medium supplemented with 10% FCS.
Cells were diluted in a total of 10ml culture medium. The total cell number was
determined using the Casy Cell Counter System.
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4.3 Analysis of cell protein expression
Gel electrophoresis (SDS-PAGE, BN-PAGE) and visualization of labeled hOATP5A1
of X. laevis oocyte samples was performed by Silvia Detro-Dassen (Institute of Phar-
macology and Toxicology, Medical Faculty, RWTH Aachen University).
The confocal microscope was operated with the assistance of Natalie Rinis and
Dirk Fahrenkamp (Institute of Biochemistry and Molecular Biology, Medical Fac-
ulty, RWTH Aachen University).
4.3.1 Antibodies
(see table 4.5)
Table 4.5: Antibodies
Target Company cat. no. Species Dilution
Primary antibodies
HA.11 clone 16B12 Covance MMS-101R mouse 1:1000
GFP Rockland 600-301-215 mouse 1:3000
Immunochemicals
Tubulin Sigma-Aldrich T0198 mouse 1:2000
HA-AlexaFluor488 Invitrogen/ A-21287 mouse 1:200
Molecular Probes
Anti-PARP Roche 11835238001 rabbit 1:1000
anti-OATP-j-N1 AbD Serotec charge 03838.2 E.coli 5 µg/ml
(ordered)
anti-SLCO5A1 Abcam ab108288 rabbit 1:1000
Secondary Antibodies
mouse IgG, HRP coupled Dako P0260 rabbit 1:1000
rabbit IgG, HRP coupled Dako P00448 goat 1:2000
anti histidine tag:HRP AbD Serotec MCA1396P mouse 1:4000
4.3.2 Flow cytometry
Flow cytometry uses the principles of light scattering, light excitation, and emission
of fluorochrome molecules to generate specific multi-parameter data from particles
and cells in the size range of 0,5 µm to 40 µm diameter. When a sample in solution is
injected into a flow cytometer, the sample is ordered by hydrodynamic focusing into
a stream of single particles that passes through one or more beams of light. Light
that is scattered in the forward direction (forward scatter, FSC) provides information
about the particle’s size, light that is scattered to the side (side scatter, SSC) provides
information about the granular content within a particle.
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Analysis of cell surface antigens
Flow cytometry can be used to detect antigens (CD-molecules) localized on the cell
surface of primary cells for the classification of subtypes.
Materials: ∼1x106 cells per sample
1x PBS/ 1% BSA/ 10% goat serum (blocking buffer)
1x PBS/ 1% BSA (FACS buffer)
mouse anti-human antibodies:
CD1a-FITC (25 µg/ml), CD80-FITC (12,5 µg/ml),
CD83-PE (50 µg/ml), CD86-FITC (50 µg/ml),
CD14-PE (25 µg/ml), CD40-FITC (6,25 µg/ml) (R&D)
isotype control antibodies:
mouse IgG1-FITC/-PE (50 µg/ml),
mouse IgG2a-PE (50 µg/ml) (R&D)
All experimental steps were performed on ice. Immature dendritic cells (suspension
cells) were washed twice in FACS buffer. Cells were blocked in blocking buffer for
15min. The antibodies were diluted in a concentration of 1 µg/ml in 100 µl FACS
buffer per sample. Cells were incubated with the antibody-solution for 30min. Then,
cells were washed twice in FACS buffer and cell pellets were dissolved in 400 µl FACS
buffer for analysis. Fluorescence was analyzed with the FACScan and the Cell Quest
Pro Software (BD, Heidelberg, Germany). The Cell Quest Pro Software was also
used for data analysis.
Analysis of cytoplasmatic antigens
Flow cytometry can be used to detect proteins localized in the cell by fluorescence
with specific antibodies which are linked to a fluorescent dye. When these cells pass
a laser beam in the flow cytometer the emitted light is detected.
Materials: 1x106 cells per sample
1x PBS
Trypsin/EDTA
cell culture medium with 10% FCS
1x PBS/1% bovine serum albumin (BSA)
1x PBS/1% BSA/0,03% saponin
antibody, mouse monoclonal anti-HA-AlexaFluor488
86 Materials and Methods
FlpIn T-Rex-Hela cells expressing hSLCO5A1WT/L33F-HA were washed once with
1xPBS and were detached from the culture dish surface with Trypsin/EDTA. Trypsin
was inactivated by addition of fresh medium to the detached cells. Cells were pel-
leted by centrifugation at 2000 rpm for 4min and washed once with 1xPBS. Cells
were washed twice with 1xPBS/1% BSA and were blocked in 1xPBS/1% BSA or
1x PBS/1% BSA/0,03% saponin for 30min at RT. Saponin was used for membrane
permeabilization due to the fact that the C-terminal HA-tag is localized intracel-
lularly. The antibody was diluted 1:200 in 100 µl 1xPBS/1% BSA or 1x PBS/1%
BSA/0,03% saponin and cells were incubated with this antibody-solution for 1h at
RT in the dark. Cells were washed twice with 1x PBS/1% BSA and were pelleted
by centrifugation at 2000 rpm for 4min. Cell pellets were dissolved in 400 µl 1x
PBS/1% BSA and cell solutions were transferred to measuring tubes. Fluorescence
was analyzed with the FACScan and the Cell Quest Pro Software (BD, Heidelberg,
Germany). The Cell Quest Pro Software was also used for data analysis.
Determination of apoptotic cells
In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is translo-
cated from the inner to the outer leaflet of the plasma membrane, thereby exposing
PS to the external cellular environment. Annexin V is a 35-36 kDa Ca2+ dependent
phospholipid-binding protein that binds to cells with exposed PS. Staining of cells
with FITC Annexin V is used in conjunction with the vital dye propidium iodide
(PI) to distinguish between early (PI negative, FITC Annexin V positive) and late
apoptotic cells (PI positive, FITC Annexin V positive). Viable cells with intact
membranes exclude PI, wheras the membranes of dead and damaged cells are per-
meable to PI. Cells that stain negative for both FITC Annexin V and PI are alive
and not undergoing measurable apoptosis.
To analyze apoptotic cells by flow cytometry the Annexin V-FITC Apoptosis Detec-
tion Kit I (BD, Heidelberg, Germany) was used. Cells were washed twice with cold
PBS and then resuspended in 1x Binding buffer at a concentration of approximately
1x106 cells/ml. 100 µl per sample of the solution was transferred to a measuring
tube. 5 µl of FITC Annexin V and 5 µl PI were added. Cells were gently vortexed
and incubated for 15min at RT in the dark. 400 µl of 1x Binding buffer was added
to each tube. Analysis was performed with the FACScan Flow cytometer using the
Cell Quest Pro Software (BD, Heidelberg, Germany). The Cell Quest Pro Software
was also used for data analysis.
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4.3.3 Confocal Fluorescence Microscopy
Stable Hela cells expressing hOATP5A1-YFP were seeded in 12-well plates on cover-
slips. On day two hOATP5A1 expression was induced by adding 1 µg/ml tetracycline.
After 24h cells were washed twice with ice-cold PBS supplemented with 1mM MgCl2
and 0,1mM CaCl2. Cells were fixed with 3,7% paraformaldehyde for 15min, washed
again with PBS and quenched with PBS containing 50mM NH4Cl for 5min in the
dark. After another washing step with PBS, cover-slips were stained with DAPI
(1:5000 in 1x PBS) (AppliChem/Biochemica, Darmstadt, Germany) for 5min in the
dark. Then, cover-slips were washed three times with 1xPBS and once with distilled
water and were embedded in Fluorescent Mounting Medium (Dako, Hamburg, Ger-
many). Object slides were left at 4°C over night in the dark. Fluorescence of YFP
(514 nm) and DAPI (405 nm) was determined by confocal laser microscopy on a Zeiss
LSM710 (Jena, Germany). The images were processed with the software ZEN2009
(Zeiss, Jena, Germany).
4.3.4 Enzyme-linked Immunosorbent assay (ELISA)
Human IL-8 was quantified in cell culture supernatants of antibiotic-stimulated
moDCs using the Quantikine IL-8 immunoassay (R&D-Systems, Wiesbaden, Ger-
many) according to the manufacturer’s instructions.
4.3.5 Preparation of cell protein lysates
FlpIn T-Rex-Hela cells
RIPA buffer: 10mM Tris/HCl pH 7,4
0,1% SDS
150mM NaCl
1% NP40
1% sodium deoxycholate
0,5% aprotinin
Proteinase inhibitors: 4mM Pefabloc SC Plus (Roche, Mannheim, Germany)
PSC-protector (Roche)
5 µg/ml aprotinin
2,5 µg/ml pepstatin
2,5 µg/ml leupeptin
1mM sodium-ortho-vanadate
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Hela cells were lysed on ice using RIPA buffer supplemented with proteinase in-
hibitors (AppliChem, Darmstadt, Germany). After mixing thoroughly, samples were
incubated for 30min on ice and centrifuged for 15min at 4°C and 14000 rpm. Su-
pernatants were collected. Protein concentration was determined using the BCA
protein assay kit (Thermo Scientific, Germany) according to the manufacturer’s rec-
ommendations. Aliquoted protein lysates were frozen at -80°C.
Xenopus laevis oocytes
Materials: 1,5ml reaction tubes
(Safe Lock, Sarstedt, Nuembrecht, Germany)
Homo-buffer: 0,1M phosphate buffer, pH 8,0
10mM iodacetamid (Sigma Chemicals, St. Louis, USA)
1% (w/v) digitonin
proteinase inhibitors:
0,1mM Pefabloc-SC (Roth, Karlsruhe, Germany)
5 µM pepstatin (Biomol, Hamburg, Germany)
10 µM leupeptin (Biomol)
10 µM antipain (Biomol)
Ni2+-incubation buffer: Ni2+-NTA-agarose-beads (Qiagen, Hilden, Germany)
1M imidazole
0,1M phosphate buffer
proteinase inhibitors (see homo-buffer)
1% (w/v) digitonin
Wash buffer: 0,1M phosphate buffer
1mM iodacetamid
0,1mM Pefabloc-SC
20-25mM imidazole
0,2% (w/v) digitonin
Elution buffer: 250mM imidazole (pH 7,4)
0,5% digitonin
Protein extraction of His-tagged proteins was performed by nickel-nitrilo acetic acid
(Ni-NTA) agarose (Qiagen, Hilden, Germany) chromatography. 10 oocytes per group
were purified. All purification steps were carried out on ice (4°C). Every group of
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oocytes were transferred to 1,5ml reaction tubes and excess liquid was removed.
Oocytes were homogenized in Homo-buffer by pipetting up and down. Lysates were
incubated on ice for 15min and vortexed in between. Then, samples were centrifuged
for 10min at 13000 rpm. Approximately 150 µl supernatant per sample was trans-
ferred to new reaction tubes and centrifuged again for 10min at 13000 rpm. 100 µl
supernatant per sample was transferred to new reaction tubes containing 30 µl of
washed Ni2+-beads, 5 µl 1M imidazol, and 400 µl incubation buffer (phosphate buffer
+ 1% digitonin) plus proteinase inhibitors. During incubation of the reaction mix
for 60min at RT in an overhead shaker (REAX2, Heidolph, Kelheim, Germany), free
electron pairs of the six histidines formed chelate complexes with the immobilized
Ni2+ ions. After incubation, the mix was washed 5 times with 1ml wash-buffer.
Native elution was performed with 2x 50 µl elution buffer. To this effect, washed Ni-
beads were incubated with 50 µl elution buffer for 15min at RT on an orbital shaker
and centrifuged afterwards. The supernatant was transferred into a new reaction
tube and the elution process was repeated with the remaining agarose-beads (fig.
4.11).
4.3.6 Deglycosylation of Glycoproteins
Deglycosylation was performed with the endopeptidases EndoH & PNGaseF (NEB,
Frankfurt/Main, Germany). EndoH is an endoglycosidase which removes high mannose-
type sugars characteristic for proteins that have not yet left the ER, whereas PNGase
F releases complex-type carbohydrates from both core- and complex-glycosylated
proteins of ER and Golgi. To investigate the glycosylation state of the proteins,
samples were first denatured with 5x GLB (Laemmli buffer) + 5% DTT for 15min
at 56°C. Then, samples were treated with either endoglycosidase H (EndoH) for
2h in the presence of reducing SDS sample buffer or PNGase F for 2h in the pres-
ence of reducing SDS sample buffer and 1% (w/v) Nonidet P40 to counteract the
SDS-mediated inactivation of PNGaseF. After deglycosylation with EndoH, the same
amount of NP40 as used for deglycosylation with PNGaseF was added to the EndoH
samples to avoid changed running conditions.
4.3.7 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was performed as described by Laemmli [66].
The denaturing SDS-PAGE separates proteins according to their molecular size. The
anionic detergent SDS denatures higher molecular protein structures, and confers a
negative charge to each protein in proportion to its mass. By this, the proteins are
separated according to their protein size towards the anode.
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Figure 4.11: Expression and isolation of His-tagged membrane proteins in Xenopus laevis
oocytes.
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FlpIn T-Rex-Hela cells
sample-buffer (2x): 20% glycerol
10% SDS
0,16M Tris/HCl, pH 6,8
0,25% bromophenol blue
8% β-mercaptoethanol (freshly added before electrophoresis)
Laemmli-buffer (4x): 20% glycerol
4% SDS
0,125M Tris/HCl, pH 6,8
0,002% bromophenol blue
10% β-mercaptoethanol (freshly added before electrophoresis)
electrophoresis-buffer: 1x Tris/glycine/SDS buffer
(10x, Bio-Rad, München, Germany)
Protein ladder: Page RulerTM Prestained Protein Ladder
10-170 kDa (Fermentas, St. Leon-Rot, Germany)
Protein lysates were mixed 1:4 with Laemmli buffer and incubated for 30min at
37°C to denature the proteins. 13 µg of each deglycosylated or control sample and
40 µg of total cell protein per hOATP5A1-HA/-YFP sample were separated by SDS-
PAGE on discontinous gels consisting of a 4% stacking gel and a 7,5% separation gel.
The proteins were separated at 200V using a Mini-PROTEAN Tetra electrophoresis
system (Bio-Rad, München, Germany).
Xenopus laevis oocytes
SDS sample buffer (5x): 310mM Tris/HCl, pH 6,8
10% LiDS (lithium dodecyl sulfate)
0,05% bromophenol blue or without dye
50% glycerol
electrophoresis buffer: 25mM Tris
192mM Glycin
0,1% SDS
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For SDS-urea PAGE (6M urea), native elution samples were mixed with SDS sample
buffer in the presence or absence of 20mM DTT and incubated for 15min at 56°C.
DTT was added to cleave disulfide bridges between cysteine residues. Binding of
LiDS to the proteins induces a dissoziation of the proteins to their subunits. Samples
were electrophoresed in parallel with 35S-labeled protein standards and with the
molecular-mass marker All Blue Standard (BioRad, München, Germany) in 4-10%
gradient continous polyacrylamide gels. Proteins were separated at an input voltage
of 100V and a running voltage of 120-150V over a period of 2-3h. Gels were directly
scanned on an IR scanner. Then, gels were fixed in 25% isopropanol and 10% acetic
acid for approximately 20min and dried for 90-120min at 80°C.
4.3.8 Blue native polyacrylamide gel electrophoresis (BN-PAGE)
BN-PAGE was performed according to Schaegger and von Jagow [131].
BN-PAGE was used to determine native protein masses and oligomeric states of
multiprotein complexes. Coomassie G-250 is used as a charge-shift molecule. The
dye binds to membrane proteins at their hydrophobic sites and confers a negative
charge without denaturing. During migration to the anode, protein complexes are
separated according to molecular mass and/or size and high resolution is obtained
by the decreasing pore size of a polyacrylamide gradient gel [118].
cathode buffer: 50mM Tricin
15mM BisTris
pH 7,0
0,002% Serva Blue G (added shortly before electrophoresis)
anode buffer: 50mM BisTris
staining solution: 1 g Coomassie Blue R-250
450ml methanol
450ml water
100ml glacial acetic acid
BN-PAGE of X. laevis oocyte samples was performed immediately after protein pu-
rification in the presence of 0,2% (w/v) Coomassie blue G250. The samples were
treated with 0,01-0,1% (w/v) SDS for 1h at 37°C to induce possible partial disso-
ciation of the membrane transporter complexes. Samples were electrophoresed in
parallel with 35S-labeled protein standards (also treated with and without SDS) in
4-16% gradient continous polyacrylamide gels. Proteins were separated at 30V over
a period of approximately 15h. For visualization of membrane-bound proteins, gels
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were completely destained with a solution of 50mM NH4HCO3 in 1:1 water and
acetonitrile under continous agitation. Destaining solution was changed after 2h to
remove the Coomassie dye. After 48h the destaining solution was replaced by phos-
phate buffer pH 8,0 and incubated for 1h before scanning on an IR scanner. For
the subsequent visualization of 35S-labeled proteins, gels were dried for 60-120min
at 80°C.
4.3.9 Visualization of labeled OATP5A1
After BN-PAGE and SDS-PAGE, gels were scanned directly on an IR (infrared)
scanner (Odyssey, LI-COR Biosciences, Bad Homburg, Germany) to visualize the
membrane-bound proteins. For the subsequent visualization of 35S-labeled proteins,
the gels were dried, exposed to a phosphor screen, and scanned on a PhosphorImager
(Storm 820, GE Healthcare, Freiburg, Germany). Analysis and processing of the gel
images was performed with the software Image QuantTM (GE Healthcare, Freiburg,
Germany).
4.3.10 Western Blot
Blotting-buffer: 1x Tris/glycine buffer
(10x, Bio-Rad, München, Germany)
20% methanol (Sigma)
PBS-T: 1x PBS
0,1% Tween-20 (AppliChem)
Before electrophoresis, the SDS-gel, sponges, and ‘Whatman-filters’ were pre-incubated
in blotting buffer for 15min. A PVDF membrane (Bio-Rad) was pre-incubated for
a few seconds in methanol, then for 5min in water, and also for 15min in blot-
ting buffer. The SDS-gel and the PVDF membrane were placed between the soaked
‘Whatman-filters’ and sponges (‘sandwich’). Proteins were electrophoretically trans-
ferred from the SDS-gel onto a PVDF membrane by wet blotting at 100V for ap-
proximately 60min. The membrane was washed three times in PBS-T.
Visualization of proteins
PBS-T: 1x PBS
0,1% Tween-20 (AppliChem)
Blocking-buffer: PBS-T
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5% BSA or 5% ECL Blocking Agent (Amersham/GE)
Stripping-buffer: 62,5mM Tris/HCl, pH 6,7
20% SDS (AppliChem)
0,8% β-mercaptoethanol (freshly added) (AppliChem)
After washing, the membrane was stained with Ponceau-S solution (AppliChem)
for 5min to visualize the protein bands and to mark the bands of the protein stan-
dard. Then, the membrane was destained in PBS-T and incubated in blocking-buffer
overnight at 4°C to saturate all free protein binding sites. After blocking, the mem-
brane was washed three times with PBS-T. The blot was probed with a dilution of
the primary antibody in PBS-T for 2h at RT, was washed three times with PBS-
T, and was incubated with a dilution of a horse radish peroxidase (HRP)-coupled
secondary antibody in PBS-T for 1h at RT. The secondary antibody binds to the in-
variable part of the primary antibody. Again, the membrane was washed three times
in PBS-T before visualizing the protein bands using enhanced chemiluminescence
(ECL) (ECL/ ECL Plus kit, Amersham/ GE Healthcare) with a computer-assisted
camera (LAS-3000, Fuji). HRP catalyzes a chemical reaction of substrates found in
the ECL kit which results in the emission of light (chemiluminescence).
To normalize sample loading, blots were stripped and re-probed with monoclonal
anti-tubulin antibody (Sigma-Aldrich, St. Gallen, Switzerland) and the appropriate
secondary antibody.
4.4 Transport assay in Xenopus laevis oocytes
Eight to twelve oocytes were microinjected with 50 nl of cRNA (0,03-1 µg/µl) of each
construct (pNKS4-hSLCO5A1WT and pNKS4-hSLCO5A1L33F) or with Tris-HCl as a
control and were incubated at 19°C in sterile frog Ringer’s solution (ORI) supple-
mented with 50 µg/ml gentamycin for 48h. Oocytes were washed in ORI buffer and
placed in reaction vessels coated with oocyte-homogenate. They were incubated with
100 µl of ORI buffer containing 1 µCi/ml Tritium-labeled substrate and 0,04 µCi/ml
[14C]sucrose at room temperature (table 4.6). [14C]sucrose served as internal leakage
control, because intact oocytes are almost impermeable to sucrose. Reaction was
stopped after 30min by adding ice-cold ORI buffer and oocytes were washed three
times in ice-cold ORI. Then oocytes were placed separately in scintillation vials
(Packard Instrument, CT, USA) and were lysed with 250 µl of 5% SDS (Roth, Karl-
sruhe, Germany) over night while continously shaking. Each scintillation vial was
filled with 3ml scintillation fluid (Zinsser Analytic, Frankfurt, Germany), incubated
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Table 4.6: Radioactive transport substrates
Radioactive transport substrates
substance specific activity company
3H-prostaglandin E2 6,73 TBq/mmol Amersham (GE Healthcare,
3H-arachidonic acid 7,99 TBq/mmol Freiburg, Germany)
14C-sucrose 14,8-25,9 GBq/mmol Perkin Elmer (Waltham,
3H-leukotriene C4 3,7-8,88 TBq/mmol Massachusetts, USA)
3H-estradiol-17β-D- 1,11-2,22 TBq/mmol
glucoronide
3H-estrone-3-sulfate 1,61 TBq/mmol
3H-[D-penicillamine2,5]- 1,11-2,22 TBq/mmol
enkephalin (DPDPE)
3H-taurocholic acid 1-5 Ci/mmol
3H-digoxin 20 Ci/mmol ARC (American Radiolabeled
3H-ouabain 30,6 Ci/mmol Chemicals, St. Louis,
3H-methotrexate 15 Ci/mmol MO, USA) via
3H-benzylpenicillin 25 Ci/mmol Hartmann Analytic
3H-dehydroepiandros- 19,5 mCi/mmol (Braunschweig, Germany)
terone-3-sulfate (DHEAS)
for 1h in the dark, mixed, and radioactivity was measured using a Beckman scin-
tillation counter (10min/sample) (Beckman LS6000SC, Beckman Coulter, Krefeld,
Germany).
4.5 Statistical analysis
Statistical Analysis was performed with Sigma Plot Version 11.0 software (Systat
Software GmbH, Erkrath, Germany). *p<0,05; **p<0,005. Data sets were tested
for significance using the Student’s Paired t-test except for THP-1 samples stimu-
lated with antibiotics. For THP-1 samples, One Way Repeated Measures Analysis of
Variance (ANOVA) was used to test the null hypothesis that there are no differences
among all the treatments on the same group of subjects. A multiple comparison test
was run versus a control group (medium or DMSO) according to the Holm-Sidak
method.
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5. Summary
Adverse drug reactions (ADRs), which include drug allergic reactions, are a common
clinical problem. Delayed-type hypersensitivity (DTH) reactions are T-cell-mediated
type IV allergic reactions, which generally occur after 24h to 72h of the drug intake,
and the skin is the major organ targeted by these reactions. Dendritic cells (DCs)
represent a key player in the elicitation of a T cell response by presenting anti-
gens to T cells. Low-molecular weight drugs are only recognized as antigens if they
are covalently bound to proteins, such as serum albumin, thus, building a hapten-
carrier-complex. In contrast, prohaptens need prior metabolization to become the
nominative antigen. Furthermore, the drug has to be internalized into the cell. Po-
lar substances are transported by specific transporter proteins. The organic anion
transporting polypeptide (OATP) family (gene symbol: SLCO) represents influx
transmembrane transporters expressed in various tissues, including the liver, kid-
ney and brain. They mediate the sodium-independent transport of a diverse range
of mainly amphiphatic organic compounds, including bile acids, steroid conjugates,
thyroid hormones, anionic peptides, and numerous other drugs.
The first part of this thesis analyzed whether the sensitization potential of drugs by
antigen-presenting cells (APCs) can be measured in vitro and whether these systems
are also capable to detect drugs acting as prohaptens. In addition to animal-based
experiments and clinical studies, in vitro models could help to evaluate the sensitiz-
ing potential of novel drug compounds. Model compounds, such as beta-lactams and
sulphonamides, drugs most frequently involved in DTH reactions, were co-incubated
with THP-1, MUTZ-LC, or primary monocyte–derived dendritic cells (moDCs) for
48h. Subsequently, expression of selected marker genes (IL-8, IL-1β, CES1, NQO1,
GCLM, PIR and TRIM16) was studied by quantitative real time PCR. Benzylpeni-
cillin and phenoxymethylpenicillin were recognized as sensitizing compounds because
they are capable of inducing the mRNA expression of these genes in moDCs and in
THP-1 cells (except for IL-8) but not in MUTZ-LC. Ampicillin stimulated the ex-
pression of some marker genes in moDCs and THP-1 cells. Sulfamethoxazole (SMX)
did not affect the expression of these genes in THP-1 cells. However, in moDCs,
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PIR was enhanced and there was an increase of the release of IL-8. These data
reveal that novel in vitro DC based assays might play a role in the evaluation of
the allergenic potential of novel drug compounds, but these systems seem to lack the
ability to detect the sensitizing potential of prohaptens such as SMX. Regarding their
sensitivity, moDCs seem to be superior compared with THP-1 and MUTZ-3 cell lines.
The second part of this thesis analyzed the human OATP family member OATP5A1,
a twelve transmembrane-spanning polypeptide, because preliminary studies revealed
that the expression of this transporter compared to other OATPs was highly in-
creased in primary mature DCs. Due to the lack of a suitable commercially available
antibody, protein characterization and function have not yet been determined. It was
the aim of this study to molecularly characterize human OATP5A1 expressed in two
expression systems - genetically modified Hela cells (‘FlpIn T-Rex-Hela’) and oocytes
of the south-african clawed frog Xenopus laevis. Furthermore, evidence regarding a
possible OATP5A1 function should be provided. Transcriptional gene expression
analysis revealed that SLCO5A1 is expressed in primary blood cells such as mono-
cytes and dendritic cells but not in macrophages. Interestingly, it could be shown
that the expression of SLCO5A1 is decreased during differentiation from monocytes
to macrophages but is increased during differentiation from monocytes to mature
dendritic cells. Moreover, SLCO5A1 expression was found to be increased in some
melanoma cell lines. The contact sensitizer TNBS decreased SLCO5A1 expression in
moDCs. Molecular analysis of OATP5A1 revealed a core- and complex-glycosylated
polypeptide monomer which could be localized in the cytosol and on the plasma
membrane. Different putative protein sizes of OATP5A1 could be observed between
Hela cells (92 kDa) and X. laevis oocytes (75 kDa). Transport studies with classical
OATP substrates could not identify any of these substrates (e. g. arachidonic acid,
estrone-3-sulfate) as target for OATP5A1. Inducible expression of OATP5A1 in Hela
cells led to an inhibitory effect on cell proliferation. Gene expression profiling with
these cells identified genes that are mainly involved in cell adhesion and in both
system- and anatomical structure development. Furthermore, a single nucleotide
polymorphism of amino acid 33 (L→F) revealed no differences regarding protein ex-
pression and function when compared to the wild-type. In conclusion, evidence is
provided that OATP5A1 might be a non-classical OATP family member, which is
involved in biological processes that require the reorganization of the cell shape, such
as differentiation and migration.
6. Zusammenfassung
Unerwünschte Arzneimittelwirkungen (UAW) beschreiben ein bekanntes klinisches
Problem. Auf Arzneimittelallergien beruhende UAW werden den Typ-B-UAW zuge-
ordnet. Dazu gehört die T-Lymphozyten-vermittelte Hypersensitivitätsreaktion vom
verzögerten Typ, die sich vor allem an der Haut manifestiert. Hierbei spielen dendriti-
sche Zellen (DCs) eine entscheidende Rolle, weil sie als Antigen-präsentierende Zellen
(APCs) die T-Zellantwort auslösen. Um den Arzneistoff als Antigen präsentieren zu
können muss das Molekül einen Hapten-Carrier-Komplex bestehend aus niedermole-
kularen Arzneistoffen, die an ein körpereigenes Trägerprotein gebunden sind, bilden.
Sogenannte Prohaptene müssen zunächst metabolisiert werden um als Antigen zu
wirken. Außerdem muss das Arzneimittel in die Zelle aufgenommen werden, was bei
polaren Substanzen über spezifische Transportproteine erfolgt. Die transmembran-
ären OATP-Transporter (Organische Anionen-Transport-Polypeptide, Gensymbol:
SLCO) stellen eine Klasse von Arzneimitteltransportern dar, die u. a. in der Leber,
der Niere und dem Gehirn vorkommen. Sie vermitteln den Natrium-unabhängigen
Influx von meist amphipathischen organischen Substanzen, z. B. von Gallensäuren,
Steroid-Konjugaten, Schilddrüsenhormonen, anionischen Peptiden oder auch von
Arzneistoffen.
Der erste Teil der vorliegenden Arbeit geht der Frage nach, inwieweit das Sensibilisie-
rungspotenzial von Arzneimitteln durch APCs in vitro gemessen werden kann und ob
auch Prohaptene erfasst werden können. Zusätzlich zu Tierversuchen und klinischen
Studien könnten in vitro-Modelle helfen das sensibilisierende Potential von neuen
Arzneistoffen zu evaluieren. Für die in vitro-Versuche wurden Modell-Substanzen,
Beta-Lactam-Antibiotika und ein Sulphonamid, mit primären von Monozyten-abstam-
menden dendritischen Zellen (moDCs), THP-1 Zellen und MUTZ-Langerhans Zellen
(MUTZ-LCs) für 48h koinkubiert. Anschließend wurde die Expression ausgewählter
Gene (IL-8, IL-1β, CES1, NQO1, GCLM, PIR, TRIM16) mittels quantitativer RT-
PCR untersucht. Benzylpenicillin und Phenoxymethylpenicillin wurden als sensibili-
sierende Arzneistoffe identifiziert, da sie die mRNA-Expression der zuvor genannten
Gene in THP-1 Zellen und moDCs, mit Ausnahme von IL-8, induzieren konnten.
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Ampicillin dagegen stimulierte nur die Expression einzelner Gene in diesen Zellen.
Sulfamethoxazol (SMX) hatte keinen Einfluss auf die Genexpression mit Ausnahme
von PIR in moDCs. Die mRNA Expression von IL-8 korrelierte mit seiner Protein-
expression in moDCs. Diese Daten zeigen, dass neu entwickelte in vitro DC-basierte
Methoden eine Rolle in der Evaluation des sensibilisierenden Potenzials von Arznei-
stoffen spielen könnten, wobei moDCs im Vergleich zu THP-1 und MUTZ-LCs besser
geeignet zu sein scheinen. Allerdings konnte mit diesen Modellen das sensibilisieren-
de Potenzial von Prohaptenen nicht nachgewiesen werden.
Im zweiten Teil dieser Arbeit wurde das zwölf Transmembransegmente-umfassende
OATP-Familienmitglied OATP5A1 untersucht, weil es sich in Vorarbeiten belegen
ließ, dass dieser Transporter im Vergleich zu anderen OATPs sehr stark von reifen
DCs exprimiert wird. Da wegen des Fehlens spezifischer Antikörper nur wenig über
diesen Transporter auf Proteinebene bekannt ist, war es Ziel dieser Arbeit OATP5A1
mithilfe von Expressionssystemen molekular zu charakterisieren und seine mögliche
Funktion näher zu analysieren. Genexpressionsstudien zeigten, dass SLCO5A1 von
primären Monozyten und dendritischen Zellen aber nicht von Makrophagen expri-
miert wird. Interessanterweise wurde die Expression von SLCO5A1 während der
Differenzierung von Monozyten zu Makrophagen verringert, jedoch während der Dif-
ferenzierung von Monozyten zu reifen dendritischen Zellen stark erhöht. Zudem zeigte
sich eine verstärkte SLCO5A1-Expression in einigen Melanom-Zelllinien. Das Kon-
taktallergen TNBS reduzierte die SLCO5A1-Expression in moDCs. Die molekulare
Analyse von OATP5A1, exprimiert in zwei Expressionssystemen (genetisch modifi-
zierten Hela-Zellen und Oozyten des Krallenfrosches Xenopus laevis), identifizierte
ein Glykoprotein-Monomer, welches sowohl im Cytosol als auch an der Zellmem-
bran lokalisiert war. Jedoch konnten unterschiedliche Proteingrößen für OATP5A1
exprimiert in Hela (92 kDa) und X. laevis (75 kDa) nachgewiesen werden. Trans-
portexperimente konnten keine klassischen OATP-Substrate (z. B. Arachidonsäure,
Estron-3-Sulfat) als zu transportierende Substanz für OATP5A1 identifizieren. Die
in Hela-Zellen induzierte OATP5A1-Expression führte zu einer geringen Hemmung
der Zellproliferation. Mithilfe einer Exon-Genarray-Expressionsstudie konnten in die-
sen Zellen durch SLCO5A1-induzierte Gene identifiziert werden, die hauptsächlich
an Prozessen der System- und anatomischen Struktur-Entwicklung, sowie der Zel-
ladhäsion beteiligt sind. Ein weiterer Befund dieser Arbeit war, dass, vergleichend
mit dem Wildtyp, ein in OATP5A1 eingeführter Einzelnukleotidpolymorphismus an
Aminosäureposition 33 (L→F) zu keinem Unterschied hinsichtlich Proteinexpression
und Funktion führte. Zusammenfassend lassen die Daten vermuten, dass OATP5A1
ein untypisches OATP-Mitglied ist, welches in biologische Prozesse, die eine Reorga-
nisation der Zellform erfordern, z. B. Differenzierung und Migration, involviert ist.
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A. Appendix
A.1 Abbreviations
°C degree celsius
µ micro
aa amino acid
Ab antibody
ABC ATP-binding cassette
ABCA6 ATP-binding cassette, subfamily A, member 6
ACTC1 actin, alpha, cardiac muscle 1
ADR adverse drug reactions
AKR1C2 aldo-keto reductase family 1, member C2
AMIGO2 adhesion molecule with Ig-like domain 2
Amp ampicillin
AP-1 activator protein 1
(JUN-jun protooncogene)
APC antigen presenting cell
ARE antioxidant response element
Arnt aryl hydrocarbon receptor nuclear translocator
ATCC American Type Culture Collection
Avg average
BD Becton Dickinson
BN-PAGE blue native-polyacrylamide gel electrophoresis
bp base pair
BSA bovine serum albumin
C3/5/6 complement component 3/5/6
CAR constitutive androstan receptor
CCL20 chemokine (C-C motif) ligand 20
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CDH13 cadherin 13, H-cadherin (heart)
cDNA copy DNA
CFH complement factor H
CLDN1 claudin 1
CMV cytomegalovirus
CPAMD8 complement3 and pregnancy zone protein-like,
α2-macroglobulin domain-containing 8
CYP1B1 cytochrome P450, family 1, subfamily B
DAPI 4‘6-Diamidino-2-phenylindol
DC dendritic cell
DMSO dimethylsulfoxide
DNA desoxyribo-nucleotide-acid
DPYSL3 dihydropyrimidinase-like 3
DSC3 desmocollin 3
DTH delayed-type hypersensitivity
DTT Dithiothreitol
ECL enhanced chemoluminescence
ECM extracellular matrix
E. coli Escherichia coli
EDTA Ethylenediaminetetraacetic acid
e. g. exempli gratia
EGF epithelial growth factor
EPCAM epithelial cell adhesion molecule
EPHA7 ephrin type-A receptor 7
EpRE electrophile response element
EPS8 epidermal growth factor receptor pathway substrate 8
et al. et alii
FACS fluorescence activated cell sorter
FC fold change
FCS fetal calf serum
FITC Fluoresceinisothiocyanat
FOS FBJ osteosarcoma oncogene
FRT Flp Recombination Target site
FSC forward scatter
FXR farnesoid X receptor
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GW Gateway cassette
HA haemagglutinin
HAS2 hyaluronan synthase 2
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
hGlyRα1 human glycine receptor subunit alpha-1
HLA human leucocyte antigen
HNF hepatocyte nuclear factor
HOXB9 homeobox B9
HPRT hypoxanthine guanine phosphoribosyl transferase
HRP horseradish peroxidase
hr(s) hour(s)
iDC immature dendritic cell
i. e. that is
IGFBP5 insulin-like growth factor binding protein 5
IL interleukin
IR infrared
kDa kilo Dalton
Keap-1 Kelch like-ECH-associated protein 1
LC langerhans cell
LB luria broth
LiDS lithium dodecyl sulfate
LPS Lipopolysaccharide
LXR liver X receptor
M molar (mol/l)
mAno1 mouse anoctamin-1
MAP1B microtubule-associated protein 1B
MCS multiple cloning site
mDC mature dendritic cell
MEF2A myocyte enhancer factor 2A
MFS Major Facilitator Superfamily
MHC major histocompatibility complex
min minutes
MMP2 matrix metallopeptidase 2
moDC monocyte-derived dendritic cell
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mRNA messenger RNA
MRP multidrug resistance-associated proteins
n nano
NACHT NAIP, CIITA, HET-E, TP1
NALP1 NACHT-LRR-PYD-containing protein 1
NEFH neurofilament, heavy polypeptide
NHEK normal human epidermal keratinocytes
Ni-NTA nickel nitrilo acetic acid
NMJ neuromuscular junction
NP-40 Nonidet P-40
Nrf2 NF-E2-related factor 2
OATP organic anion transporter protein
ORF open reading frame
OSM oncostatin M
OSMR oncostatin M receptor
PAGE polyacrylamid gel electrophoresis
Pax-6 paired box 6, transcription factor
PBMC peripheral blood mononuclear cells
PBS phosphate buffered saline
PCR polymerase chain reaction
PCDHB protocadherin beta
PDZ post-synaptic density protein (PSD95)
Drosophila disc large tumor suppressor (Dlg1)
zonula occludens-1 protein (ZO-1)
PenG benzylpenicillin
PenV phenoxymethylpenicillin
PKC protein kinase C
POU3F2 POU class 3 homeobox 2
(nervous system-specific octamer-binding
transcription factor N-Oct-3)
PPARα peroxisome proliferator-activated receptor alpha
PTPRF protein tyrosine phosphatase, receptor type, F
PXR pregnane X receptor
qRT-PCR quantitative reverse transcriptase polymerase chain reaction
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Reg. regulation
RfA DNA Reading Frame Cassette A
RFP RET finger protein
rh recombinant human
RNA ribonucleic acid
rpm rounds per minute
RPMI Roswell Park Memorial Institute
RT room temperature
S100A16 S100 calcium binding protein A16
SCC squamous cell carcinoma
SCLC small cell lung cancer
SDS sodium dodecyl sulfate
SEMA3A sema domain, immunoglobulin domain (Ig), short basic domain,
secreted, semaphorin 3A
SLAM signaling lymphocytic activation molecule
SLC1A3 solute carrier family 1 member 3
(glial high affinity glutamate transporter)
SLCO solute carrier organic anion transporter
SMX sulfamethoxazole
SNP single nucleotide polymorphisms
Sox9 SRY (sex determining region Y)-box 9
SPARC secreted protein, acidic, cysteine-rich (osteonectin)
SSC side scatter
TAGLN/PCSK7 transgelin/proprotein convertase subtilisin/kexin type 7
TBS Tris-buffered saline
TCF4 transcription factor 4
TE Tris-EDTA
Tet tetracycline
TGF-β transforming growth factor beta
TGFBI transforming growth factor, beta-induced
TGM2 transglutaminase 2
TNBS 2,4,6-trinitrobenzene sulfonic acid
TNF tumor necrosis factor
U unit
vs versus
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w/v weight per volume
WB western blot
WFDC1 WAP four-disulfide core domain 1
WT wild-type
X. Xenopus
YFP yellow fluorescent protein
YY1 Yin and Yang 1 protein (transcription factor)
z. B. zum Beispiel
ZFP42 zinc finger protein 42 homolog (mouse)
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Table A.1: Analysis of gene expression of Hela cells stably expressing hSLCO5A1 com-
pared to mock cells using the Affymetrix GeneChip Human Exon 1.0 ST array.
Transcript FC [SLCO5A1] Reg. Gene Description Genesymbol Refseq
Cluster ID vs [mock]
8151223 30,211792 up solute carrier organic anion
transporter family, mem-
ber 5A1
SLCO5A1 NM_030958
8098690 7,344609 up zinc finger protein 42 ho-
molog (mouse)
ZFP42 NM_174900
8090180 6,3791203 up mucin 13, cell surface asso-
ciated
MUC13 NM_033049
8058857 5,3928714 up insulin-like growth factor
binding protein 5
IGFBP5 NM_000599
7911231 4,8719125 up olfactory receptor, family
2, subfamily W, member 3
OR2W3 NM_001001957
7911229 4,868381 up olfactory receptor, family
2, subfamily W, member 3
OR2W3 NM_001001957
7930181 4,764688 up arsenic (+3 oxidation
state) methyltransferase
| chromosome 10 open
reading frame 32
AS3MT|C10orf32 NM_020682
7911218 4,527852 up tripartite motif-containing
58 | olfactory receptor,
family 2, subfamily W,
member 3
TRIM58|OR2W3 NM_015431
8025992 4,4089227 up zinc finger family member
788
ZNF788 NR_027049
8066214 4,158959 up transglutaminase 2 (C
polypeptide, protein-
glutamine-gamma-
glutamyltransferase)
TGM2 NM_004613
7997504 4,145767 up cadherin 13, H-cadherin
(heart)
CDH13 NM_001257
8048864 3,9234626 up chemokine (C-C motif) lig-
and 20
CCL20 NM_004591
8166611 3,3135734 up melanoma antigen family
B, 2
MAGEB2 NM_002364
7985147 2,8416505 up DnaJ (Hsp40) homolog,
subfamily A, member 4
DNAJA4 NM_018602
7908459 2,723075 up complement factor H CFH NM_000186
8033257 2,6953452 up complement component 3 C3 NM_000064
8105040 2,6588984 up oncostatin M receptor OSMR NM_003999
8114920 2,6222978 up dihydropyrimidinase-like 3 DPYSL3 NM_001197294
8135943 2,619421 up
8140668 2,5663838 up sema domain, im-
munoglobulin domain
(Ig), short basic domain,
secreted, (semaphorin) 3A
SEMA3A NM_006080
8092726 2,5568209 up claudin 1 CLDN1 NM_021101
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Transcript FC [SLCO5A1] Reg. Gene Description Genesymbol Refseq
Cluster ID vs [mock]
7957260 2,5054543 up GLI pathogenesis-related 1
| KRR1, small subunit
(SSU) processome compo-
nent, homolog (yeast)
GLIPR1|KRR1 NM_006851
8016476 2,4192357 up homeobox B9 HOXB9 NM_024017
8022692 2,3732793 up desmocollin 3 DSC3 NM_024423
7962058 2,369142 up transmembrane and tetra-
tricopeptide repeat con-
taining 1
TMTC1 NM_175861
8104930 2,3014822 up solute carrier family 1
(glial high affinity gluta-
mate transporter), mem-
ber 3
SLC1A3 NM_004172
7997582 2,2981057 up WAP four-disulfide core
domain 1
WFDC1 NM_021197
8128284 2,2859817 up EPH receptor A7 EPHA7 NM_004440
8100808 2,2834702 up sulfotransferase family 1E,
estrogen-preferring, mem-
ber 1
SULT1E1 NM_005420
7961546 2,2785645 up epidermal growth factor re-
ceptor pathway substrate 8
EPS8 NM_004447
8117301 2,2755892 up histone cluster 1, H2ba HIST1H2BA NM_170610
8108744 2,2554677 up protocadherin beta 14 PCDHB14 NM_018934
8108683 2,2208428 up protocadherin beta 2 PCDHB2 NM_018936
7920291 2,214168 up S100 calcium binding pro-
tein A16
S100A16 NM_080388
7950906 2,1988966 up cathepsin C CTSC NM_001814
7962579 2,1802745 up adhesion molecule with Ig-
like domain 2
AMIGO2 NM_001143668
7974835 2,1631925 up protein kinase C, eta PRKCH NM_006255
7958842 2,1588798 up
8108716 2,1456244 up protocadherin beta 16 PCDHB16 NM_020957
8051583 2,0751958 up cytochrome P450, family 1,
subfamily B, polypeptide 1
CYP1B1 NM_000104
7900792 2,0665143 up protein tyrosine phos-
phatase, receptor type,
F
PTPRF NM_002840
8072382 2,0590732 up oxysterol binding protein 2 OSBP2 NM_030758
8046815 2,048808 up zinc finger protein 804A ZNF804A NM_194250
7992861 2,0247858 up
8154233 2,0219495 up CD274 NM_014143
7944082 2,014723 up transgelin | proprotein
convertase subtilisin/kexin
type 7
TAGLN|PCSK7 NM_001001522
7956269 2,0133724 up
8072229 2,0132298 up neurofilament, heavy
polypeptide
NEFH NM_021076
8092541 2,0126252 up lipase, member H LIPH NM_139248
7995681 2,0097687 up matrix metallopeptidase
2 (gelatinase A, 72kDa
gelatinase, 72kDa type IV
collagenase)
MMP2 NM_004530
8149248 2,00845 down
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Transcript FC [SLCO5A1] Reg. Gene Description Genesymbol Refseq
Cluster ID vs [mock]
8106098 2,010132 down microtubule-associated
protein 1B
MAP1B NM_005909
7911854 2,0689807 down KIAA0495 NR_033711
8023415 2,088585 down transcription factor 4 TCF4 NM_001083962
8163839 2,0930207 down complement component 5 C5 NM_001735
7950162 2,0998118 down phosphodiesterase 2A,
cGMP-stimulated
PDE2A NM_002599
7997642 2,108236 down cysteine-rich secretory pro-
tein LCCL domain con-
taining 2
CRISPLD2 NM_031476
8114898 2,1371043 down
8055314 2,169951 down LY6/PLAUR domain con-
taining 1 | G protein-
coupled receptor 39
LYPD1|GPR39 NM_144586
8108217 2,1811423 down transforming growth fac-
tor, beta-induced, 68kDa
TGFBI NM_000358
7987315 2,1928756 down actin, alpha, cardiac mus-
cle 1
ACTC1 NM_005159
7959330 2,196594 down WD repeat domain 66 WDR66 NM_144668
8152617 2,2164152 down hyaluronan synthase 2 HAS2 NM_005328
7981514 2,2531073 down AHNAK nucleoprotein 2 AHNAK2 NM_138420
8114900 2,2627628 down protein phosphatase 2, reg-
ulatory subunit B, beta
PPP2R2B NM_004576
8067652 2,29772 down eukaryotic translation
elongation factor 1 alpha 2
EEF1A2 NM_001958
8157231 2,3248549 down
8098439 2,341663 down epithelial cell adhesion
molecule
EPCAM NM_002354
8004152 2,3520849 down WSC domain containing 1 WSCD1 NM_015253
7970793 2,4908414 down solute carrier family 46,
member 3
SLC46A3 NM_181785
8131844 2,7798915 down glycoprotein (transmem-
brane) nmb
GPNMB NM_001005340
7942332 3,0415804 down folate receptor 1 (adult) FOLR1 NM_016724
8171248 3,3562174 down Kallmann syndrome 1 se-
quence
KAL1 NM_000216
7975779 3,4330106 down FBJ murine osteosarcoma
viral oncogene homolog
FOS NM_005252
126 Appendix
A.3 Curriculum vitae
Name: Sebastian
Vorname: Katrin
Geburtsdatum: 16.04.1984
Geburtsort: 37327 Leinefelde
Nationalität: Deutsch
Wissenschaftliche Tätigkeit:
seit 05/2009 Im Rahmen einer Promotion wissenschaftliche Mitarbeiterin
am Institut für Dermatologie der medizinischen Fakultät
der RWTH Aachen University
Auslandsaufenthalt:
03/2008-01/2009 „Work and Travel New Zealand“
Studium:
11/2006-01/2008 Diplomarbeit am Institut für Biochemie II der medizinischen
Fakultät der Friedrich-Schiller-Universität Jena (FSU),
Arbeitsgruppe PD K. H. Friedrich,
Erlangung des Grades Diplom-Biochemikerin
10/2002-01/2008 Diplom-Studium der Biochemie/Molekularbiologie
an der FSU Jena
Schulausbildung:
2000-2002 Abitur am Johann-Georg-Lingemann-Gymnasium
Heilbad Heiligenstadt
1994-2000 Besuch des Gottfried-Wilhelm-Leibniz-Gymnasiums Leinefelde
1990-1994 Besuch der Grundschule in Leinefelde
A.4 Publications 127
A.4 Publications
Sebastian, K., Borowski, A., Kuepper, M., Friedrich, K. (2008). Signal transduc-
tion around thymic stromal lymphopoietin (TSLP) in atopic asthma. Cell Commun.
Signal., 6(5), 1-8
Wohlmann, A., Sebastian, K., Borowski, A., Krause, S., Friedrich, K. (2010).
Signal transduction by the atopy-associated human thymic stromal lymphopoietin
(TSLP) receptor depends on Janus kinase function. Biol. Chem., 391(2-3), 181-6
Heise, R., Skazik, C., Marquardt, Y., Czaja, K., Sebastian, K., Kurschat, P.,
Gan, L., Denecke, B., Ekanayake-Bohlig, S., Wilhelm, K. P., Merk, H. F., Baron, J.
M. (2012). Dexpanthenol modulates gene expression in skin wound healing in vivo.
Skin Pharmacol. Physiol., 25(5), 241-248
Sebastian, K., Ott, H., Zwadlo-Klarwasser, G., Skazik-Voogt, C., Marquardt, Y.,
Czaja, K., Merk, H. F., Baron, J. M. (2012). Evaluation of the sensitizing potential
of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary
monocyte-derived dendritic cells. Toxicol. Appl. Pharmacol., 262(3), 283-92
128 Appendix
A.5 Eidesstattliche Erklärung
Ich erkläre eidesstattlich, dass ich die vorliegende Dissertation selbstständig verfasst
und nur unter Zuhilfenahme der angegebenen Literatur angefertigt habe. In An-
spruch genommene Personen-bezogene Hilfen wurden in der Dissertation benannt.
Des Weiteren erkläre ich, dass die vorliegende Dissertation in keiner anderen Weise
als vergleichbare Prüfungsarbeit verwendet wurde.
Aachen, den 13. März 2013 Katrin Sebastian
A.6 Danksagung 129
A.6 Danksagung
Danken möchte ich in erster Linie den Betreuern meiner Promotion, Prof. Hans
F. Merk, Prof. Jens Malte Baron sowie Prof. Gabriele Zwadlo-Klarwasser für Ihre
Unterstützung, Ihr Vertrauen und Ihre Diskussionsbereitschaft. Vielen Dank sowohl
für die naturwissenschaftliche, als auch die klinische Expertise.
Für die Übernahme des Ko-Referats danke ich recht herzlich Herrn Prof. Elling.
Meiner Arbeitsgruppe, der Derma, möchte ich besonders danken für Ihre Gesprächs-,
sowie Hilfsbereitschaft in allen Laborsituationen und darüberhinaus. Vielen Dank an
Katharina Czaja, Yvonne Marquardt, Philipp Amann, Claudia Skazik-Voogt, Ruth
Heise und Sebastian Huth. Hagen Ott danke ich für seine allergologische Expertise.
Dankeschön auch an die weiteren Mitarbeiter der Dermatologie, insbesondere für die
abwechslungsreichen Mittagessen.
Weiterhin danke ich Prof. Günther Schmalzing für seine pharmakologische Hilfe.
Ein besonderer Dank gilt Silvia Detro-Dassen für ihre unermüdliche Hilfs- und Dis-
kussionsbereitschaft. Ein großes Dankeschön auch an Elisa Zimmer für viele nette
Gespräche.
Dank gebührt ebenfalls Prof. Müller-Newen, Natalie Rinis und Dirk Fahrenkamp.
Vielen Dank an meine Aachener Freunde Andreas, Katharina, Christian, Elisa und
Achim.
Vielen Dank auch an Nadja für ihre musikalische Begleitung.
Meinem Partner danke ich für seine Hilfe bei LATEX sowie für seine Unterstützung
bei all meinen Entscheidungen und für seine Liebe.
Ohne die rückhaltlose Unterstützung meiner Familie wäre all dies nicht möglich ge-
wesen. Ihnen gebührt der größte Dank.
